CN105747218A - 低热量、高蛋白质营养组合物及其应用方法 - Google Patents
低热量、高蛋白质营养组合物及其应用方法 Download PDFInfo
- Publication number
- CN105747218A CN105747218A CN201610136619.4A CN201610136619A CN105747218A CN 105747218 A CN105747218 A CN 105747218A CN 201610136619 A CN201610136619 A CN 201610136619A CN 105747218 A CN105747218 A CN 105747218A
- Authority
- CN
- China
- Prior art keywords
- protein
- tube feed
- source
- vitamin
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 175
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 174
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 109
- 235000016709 nutrition Nutrition 0.000 title abstract description 39
- 235000012041 food component Nutrition 0.000 claims abstract description 37
- 239000005428 food component Substances 0.000 claims abstract description 35
- 230000036541 health Effects 0.000 claims abstract description 25
- 235000018102 proteins Nutrition 0.000 claims description 170
- 239000002773 nucleotide Substances 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 230000003203 everyday effect Effects 0.000 claims description 56
- 230000008569 process Effects 0.000 claims description 48
- 241000196324 Embryophyta Species 0.000 claims description 27
- 229940088594 vitamin Drugs 0.000 claims description 27
- 229930003231 vitamin Natural products 0.000 claims description 27
- 235000013343 vitamin Nutrition 0.000 claims description 27
- 239000011782 vitamin Substances 0.000 claims description 27
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 25
- 235000010755 mineral Nutrition 0.000 claims description 25
- 239000011707 mineral Substances 0.000 claims description 25
- 235000015097 nutrients Nutrition 0.000 claims description 21
- 235000013339 cereals Nutrition 0.000 claims description 19
- 230000007774 longterm Effects 0.000 claims description 18
- 229930003316 Vitamin D Natural products 0.000 claims description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 17
- 235000019166 vitamin D Nutrition 0.000 claims description 17
- 239000011710 vitamin D Substances 0.000 claims description 17
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 17
- 229940046008 vitamin d Drugs 0.000 claims description 17
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 15
- 206010008129 cerebral palsy Diseases 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 11
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 108010084695 Pea Proteins Proteins 0.000 claims description 9
- 235000013372 meat Nutrition 0.000 claims description 9
- 208000018360 neuromuscular disease Diseases 0.000 claims description 9
- 235000019702 pea protein Nutrition 0.000 claims description 9
- 239000005862 Whey Substances 0.000 claims description 8
- 102000007544 Whey Proteins Human genes 0.000 claims description 8
- 230000006931 brain damage Effects 0.000 claims description 8
- 231100000874 brain damage Toxicity 0.000 claims description 8
- 208000029028 brain injury Diseases 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 150000002215 flavonoids Chemical group 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 7
- 235000005822 corn Nutrition 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 235000013311 vegetables Nutrition 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 150000003505 terpenes Chemical class 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 4
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 244000098338 Triticum aestivum Species 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- 235000014103 egg white Nutrition 0.000 claims description 4
- 210000000969 egg white Anatomy 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 3
- 244000105624 Arachis hypogaea Species 0.000 claims description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 3
- 235000018262 Arachis monticola Nutrition 0.000 claims description 3
- 235000007319 Avena orientalis Nutrition 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 3
- 241000219739 Lens Species 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 108010079058 casein hydrolysate Proteins 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 235000020232 peanut Nutrition 0.000 claims description 3
- 150000002989 phenols Chemical class 0.000 claims description 3
- 229920002477 rna polymer Polymers 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 240000004922 Vigna radiata Species 0.000 claims description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims 1
- 235000016425 Arthrospira platensis Nutrition 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229940082787 spirulina Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 32
- 230000008901 benefit Effects 0.000 abstract description 26
- 210000000988 bone and bone Anatomy 0.000 abstract description 25
- 239000011785 micronutrient Substances 0.000 abstract description 11
- 235000013369 micronutrients Nutrition 0.000 abstract description 10
- 210000003205 muscle Anatomy 0.000 abstract description 8
- 230000000975 bioactive effect Effects 0.000 abstract description 3
- 230000001976 improved effect Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- -1 caseinate Proteins 0.000 description 30
- 235000005911 diet Nutrition 0.000 description 29
- 235000012054 meals Nutrition 0.000 description 28
- 239000002253 acid Substances 0.000 description 27
- 230000035764 nutrition Effects 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 25
- 235000019197 fats Nutrition 0.000 description 23
- 206010011985 Decubitus ulcer Diseases 0.000 description 22
- 208000004210 Pressure Ulcer Diseases 0.000 description 22
- 230000037396 body weight Effects 0.000 description 22
- 230000000378 dietary effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 230000012010 growth Effects 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 235000017807 phytochemicals Nutrition 0.000 description 15
- 229930000223 plant secondary metabolite Natural products 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 239000000306 component Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000011575 calcium Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 235000008504 concentrate Nutrition 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 230000004060 metabolic process Effects 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 239000001961 anticonvulsive agent Substances 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 239000000835 fiber Substances 0.000 description 12
- 235000013406 prebiotics Nutrition 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- 230000000474 nursing effect Effects 0.000 description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 8
- 229930003268 Vitamin C Natural products 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 235000019154 vitamin C Nutrition 0.000 description 8
- 239000011718 vitamin C Substances 0.000 description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 241000605909 Fusobacterium Species 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 229910052711 selenium Inorganic materials 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 235000011649 selenium Nutrition 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 6
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 229920002907 Guar gum Polymers 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 6
- 229950006790 adenosine phosphate Drugs 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 235000021466 carotenoid Nutrition 0.000 description 6
- 150000001747 carotenoids Chemical class 0.000 description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 6
- 235000012754 curcumin Nutrition 0.000 description 6
- 239000004148 curcumin Substances 0.000 description 6
- 229940109262 curcumin Drugs 0.000 description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000665 guar gum Substances 0.000 description 6
- 235000010417 guar gum Nutrition 0.000 description 6
- 229960002154 guar gum Drugs 0.000 description 6
- 230000007407 health benefit Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000003556 anti-epileptic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 235000012680 lutein Nutrition 0.000 description 5
- 239000001656 lutein Substances 0.000 description 5
- 229960005375 lutein Drugs 0.000 description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 5
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 5
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 4
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 4
- 241000193798 Aerococcus Species 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 4
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 4
- 241001478240 Coccus Species 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- LIKYNOPXHGPMIH-UHFFFAOYSA-N Dillapiole Chemical compound C=CCC1=C(OC)C(OC)=C2OCOC2=C1 LIKYNOPXHGPMIH-UHFFFAOYSA-N 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000194036 Lactococcus Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000192132 Leuconostoc Species 0.000 description 4
- 235000004431 Linum usitatissimum Nutrition 0.000 description 4
- 240000006240 Linum usitatissimum Species 0.000 description 4
- 244000241838 Lycium barbarum Species 0.000 description 4
- 235000015459 Lycium barbarum Nutrition 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 241000192041 Micrococcus Species 0.000 description 4
- 241000235395 Mucor Species 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 241000192001 Pediococcus Species 0.000 description 4
- 241000228143 Penicillium Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- 240000004713 Pisum sativum Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 241000235527 Rhizopus Species 0.000 description 4
- 102100038803 Somatotropin Human genes 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 4
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000037180 bone health Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000000413 hydrolysate Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 4
- 229960000511 lactulose Drugs 0.000 description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 4
- 229930013686 lignan Natural products 0.000 description 4
- 235000009408 lignans Nutrition 0.000 description 4
- 150000005692 lignans Chemical class 0.000 description 4
- 235000012661 lycopene Nutrition 0.000 description 4
- 239000001751 lycopene Substances 0.000 description 4
- 229960004999 lycopene Drugs 0.000 description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 4
- 235000021073 macronutrients Nutrition 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- 235000010930 zeaxanthin Nutrition 0.000 description 4
- 239000001775 zeaxanthin Substances 0.000 description 4
- 229940043269 zeaxanthin Drugs 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 235000016804 zinc Nutrition 0.000 description 4
- 235000007355 (-)-epicatechin Nutrition 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- 229930013783 (-)-epicatechin Natural products 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- GTBJRWFFEQJCHN-REOHCLBHSA-N (2s)-3-hydroxy-2-(hydroxyamino)propanoic acid Chemical compound OC[C@H](NO)C(O)=O GTBJRWFFEQJCHN-REOHCLBHSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000588807 Bordetella Species 0.000 description 3
- 240000002791 Brassica napus Species 0.000 description 3
- 235000011293 Brassica napus Nutrition 0.000 description 3
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 241001136487 Eurotium Species 0.000 description 3
- 229920000926 Galactomannan Polymers 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 235000009496 Juglans regia Nutrition 0.000 description 3
- 240000007049 Juglans regia Species 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000186429 Propionibacterium Species 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 229920000294 Resistant starch Polymers 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- NVLPQIPTCCLBEU-UHFFFAOYSA-N allyl methyl sulphide Natural products CSCC=C NVLPQIPTCCLBEU-UHFFFAOYSA-N 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 235000013793 astaxanthin Nutrition 0.000 description 3
- 239000001168 astaxanthin Substances 0.000 description 3
- 229940022405 astaxanthin Drugs 0.000 description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 3
- 235000012677 beetroot red Nutrition 0.000 description 3
- 239000001654 beetroot red Substances 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 235000002185 betanin Nutrition 0.000 description 3
- 230000003913 calcium metabolism Effects 0.000 description 3
- 229940071162 caseinate Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 235000004426 flaxseed Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 3
- 229940118199 levulan Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000003050 macronutrient Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 239000003075 phytoestrogen Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000021254 resistant starch Nutrition 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- 229940091258 selenium supplement Drugs 0.000 description 3
- 230000025185 skeletal muscle atrophy Effects 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 150000003538 tetroses Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 235000007219 (+)-catechin Nutrition 0.000 description 2
- 229930013915 (+)-catechin Natural products 0.000 description 2
- ATCICVFRSJQYDV-UHFFFAOYSA-N (6E,8E,10E,12E,14E,16E,18E,20E,22E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,26,30-dodecaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C ATCICVFRSJQYDV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 2
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- VFTRKSBEFQDZKX-UHFFFAOYSA-N 3,3'-diindolylmethane Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4NC=3)=CNC2=C1 VFTRKSBEFQDZKX-UHFFFAOYSA-N 0.000 description 2
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229920000310 Alpha glucan Polymers 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- QQRSPHJOOXUALR-UHFFFAOYSA-N Apiole Chemical compound COC1=CC(CC=C)=C(OC)C2=C1OCO2 QQRSPHJOOXUALR-UHFFFAOYSA-N 0.000 description 2
- 241000209763 Avena sativa Species 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000726108 Blastocystis Species 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 2
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 241000235035 Debaryomyces Species 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033892 Paraplegia Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 108010055615 Zein Proteins 0.000 description 2
- 229920002494 Zein Polymers 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 235000000183 arugula Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- KZJWDPNRJALLNS-FBZNIEFRSA-N clionasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-FBZNIEFRSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 125000004383 glucosinolate group Chemical group 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000011676 menaquinone-4 Substances 0.000 description 2
- 239000011700 menaquinone-7 Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 235000008151 pyridoxamine Nutrition 0.000 description 2
- 239000011699 pyridoxamine Substances 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229960005559 sulforaphane Drugs 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000008118 thearubigins Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 239000011135 tin Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 description 1
- YDNYEJZZJXFADP-SNVBAGLBSA-N (2r)-5-amino-2-[(4-methylphenyl)sulfonylamino]-5-oxopentanoic acid Chemical compound CC1=CC=C(S(=O)(=O)N[C@H](CCC(N)=O)C(O)=O)C=C1 YDNYEJZZJXFADP-SNVBAGLBSA-N 0.000 description 1
- SEBFKMXJBCUCAI-WAABAYLZSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2s,3s)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-WAABAYLZSA-N 0.000 description 1
- ABTRFGSPYXCGMR-KXQOOQHDSA-N (3R)-beta,psi-caroten-3-ol Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C ABTRFGSPYXCGMR-KXQOOQHDSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- UMYJVVZWBKIXQQ-QALSDZMNSA-N (4aS,6aR,6bR,8aR,12aR,12bR,14aS)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a-icosahydropicene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C=C5[C@H]4CC[C@@H]3[C@]21C UMYJVVZWBKIXQQ-QALSDZMNSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 1
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 1
- YEDFEBOUHSBQBT-UHFFFAOYSA-N 2,3-dihydroflavon-3-ol Chemical compound O1C2=CC=CC=C2C(=O)C(O)C1C1=CC=CC=C1 YEDFEBOUHSBQBT-UHFFFAOYSA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- 235000010045 3,3'-diindolylmethane Nutrition 0.000 description 1
- 229940093768 3,3'-diindolylmethane Drugs 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- GWNBMLCISLLOAU-UHFFFAOYSA-N 4-oxo-2-phenylchromene-3-carbaldehyde Chemical class O1C2=CC=CC=C2C(=O)C(C=O)=C1C1=CC=CC=C1 GWNBMLCISLLOAU-UHFFFAOYSA-N 0.000 description 1
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101150072667 Bcl3 gene Proteins 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000011297 Brassica napobrassica Nutrition 0.000 description 1
- 241000219192 Brassica napus subsp. rapifera Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 1
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 1
- 241001674939 Caulanthus Species 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 240000000399 Delphinium grandiflorum Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 241000801434 Eruca Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000246500 Gentianella aspera Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- RJIIQBYZGJSODH-QWRGUYRKSA-N Indicaxanthin Chemical compound C1=C(C(O)=O)N[C@H](C(=O)O)C\C1=C/C=[N+]/1[C@H](C([O-])=O)CCC\1 RJIIQBYZGJSODH-QWRGUYRKSA-N 0.000 description 1
- SOKRTWSMFOUWEI-UHFFFAOYSA-N Indicaxanthin Natural products OC(=O)C1CC(=C/CN2CCCC2C(=O)O)C=C(N1)C(=O)O SOKRTWSMFOUWEI-UHFFFAOYSA-N 0.000 description 1
- IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241001468189 Melissococcus Species 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- UMYJVVZWBKIXQQ-UHFFFAOYSA-N Moronic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)C=C5C4CCC3C21C UMYJVVZWBKIXQQ-UHFFFAOYSA-N 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 101100381520 Mus musculus Bcl3 gene Proteins 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 235000017879 Nasturtium officinale Nutrition 0.000 description 1
- 240000005407 Nasturtium officinale Species 0.000 description 1
- JGRJFJIJVQCUMW-HQSRNOONSA-N Neobetanin Chemical compound OC[C@H]1O[C@@H](Oc2cc3C[C@H](N(\C=C\c4cc(nc(c4)C(O)=O)C(O)=O)c3cc2O)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O JGRJFJIJVQCUMW-HQSRNOONSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- ATCICVFRSJQYDV-DDRHJXQASA-N Neurosporene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C ATCICVFRSJQYDV-DDRHJXQASA-N 0.000 description 1
- 101150022485 Nfkb1 gene Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000202223 Oenococcus Species 0.000 description 1
- 235000007171 Ononis arvensis Nutrition 0.000 description 1
- 240000002598 Ononis spinosa Species 0.000 description 1
- 235000016054 Ononis spinosa subsp spinosa Nutrition 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- ZEASWHWETFMWCV-ISBUVJFSSA-N Theaflavin 3,3'-digallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C2=CC(=CC(=O)C(O)=C2C(O)=C(O)C=1)[C@@H]1[C@@H](CC2=C(O)C=C(O)C=C2O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 ZEASWHWETFMWCV-ISBUVJFSSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000020891 alkaline diet Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- JGMPRNFEEAJLAJ-UHFFFAOYSA-N allyl methyl trisulphide Natural products CSSSCC=C JGMPRNFEEAJLAJ-UHFFFAOYSA-N 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 235000014398 anacardic acid Nutrition 0.000 description 1
- KAOMOVYHGLSFHQ-UTOQUPLUSA-N anacardic acid Chemical compound CCC\C=C/C\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O KAOMOVYHGLSFHQ-UTOQUPLUSA-N 0.000 description 1
- ADFWQBGTDJIESE-UHFFFAOYSA-N anacardic acid 15:0 Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O ADFWQBGTDJIESE-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001453 anthocyanidins Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 244000046738 asparagus lettuce Species 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- DMASLKHVQRHNES-FKKUPVFPSA-N beta-cryptoxanthin Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C DMASLKHVQRHNES-FKKUPVFPSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000000842 betacyanins Nutrition 0.000 description 1
- PDBJJFJKNSKTSW-UHFFFAOYSA-N betaxanthin Natural products NC(=O)CCC(C([O-])=O)[NH+]=CC=C1CC(C(O)=O)NC(C(O)=O)=C1 PDBJJFJKNSKTSW-UHFFFAOYSA-N 0.000 description 1
- 235000016411 betaxanthins Nutrition 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000004654 carnosol Nutrition 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- OVSVTCFNLSGAMM-KGBODLQUSA-N cis-phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/C=C/C=C(C)/CCC=C(/C)CCC=C(C)C)C)C)C)C OVSVTCFNLSGAMM-KGBODLQUSA-N 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229930016834 coumestan Natural products 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000019503 curry powder Nutrition 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 235000004211 dillapiole Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- KURVIXMFFSNONZ-WFIJOQBCSA-L disodium;[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])([O-])=O)O[C@H]1N1C(=O)NC(=O)C=C1 KURVIXMFFSNONZ-WFIJOQBCSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003826 endocrine responses Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003939 flavanonol Natural products 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 235000016241 indicaxanthin Nutrition 0.000 description 1
- CCXPAUKIWRMEET-QWRGUYRKSA-N indicaxanthin Natural products OC(=O)[C@@H]1CCCN1C=CC1=CC(=N[C@@H](C1)C(O)=O)C(O)=O CCXPAUKIWRMEET-QWRGUYRKSA-N 0.000 description 1
- 235000002279 indole-3-carbinol Nutrition 0.000 description 1
- RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 235000006826 lariciresinol Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000018842 neobetanin Nutrition 0.000 description 1
- KRZLUOUGQYWELW-UHFFFAOYSA-N neobetanin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1)O)=CC(CC\2C([O-])=O)=C1[N+]/2=C/C=C1C=C(C(O)=O)NC(C(O)=O)=C1 KRZLUOUGQYWELW-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 235000008665 neurosporene Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000008531 oleocanthal Nutrition 0.000 description 1
- VPOVFCBNUOUZGG-VAKDEWRISA-N oleocanthal Chemical compound C\C=C(\C=O)[C@@H](CC=O)CC(=O)OCCC1=CC=C(O)C=C1 VPOVFCBNUOUZGG-VAKDEWRISA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- QULMBDNPZCFSPR-UHFFFAOYSA-N petunidin chloride Chemical compound [Cl-].OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 QULMBDNPZCFSPR-UHFFFAOYSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000011765 phytoene Nutrition 0.000 description 1
- 235000002677 phytofluene Nutrition 0.000 description 1
- OVSVTCFNLSGAMM-UZFNGAIXSA-N phytofluene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=C\C=C(/C)\C=C\C=C(C)CCC=C(C)CCC=C(C)C OVSVTCFNLSGAMM-UZFNGAIXSA-N 0.000 description 1
- ZYSFBWMZMDHGOJ-SGKBLAECSA-N phytofluene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)C=CC=C(/C)CCC=C(C)C)C)C)C)C ZYSFBWMZMDHGOJ-SGKBLAECSA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001190 pomegranate ellagitannin Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013167 probetanin Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- LMIBIMUSUFYFJN-RSVYENFWSA-N punicalagin Natural products O[C@@H]1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3c4c(O)cc5OC(=O)c6c(c(O)c(O)c7OC(=O)c4c5c67)c8c(O)c(O)c(O)cc8C(=O)O[C@H]2[C@@H]9OC(=O)c%10cc(O)c(O)c(O)c%10c%11c(O)c(O)c(O)cc%11C(=O)O[C@@H]19 LMIBIMUSUFYFJN-RSVYENFWSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 235000010272 rosemarinol Nutrition 0.000 description 1
- 235000009514 rubixanthin Nutrition 0.000 description 1
- 239000000455 rubixanthin Substances 0.000 description 1
- ABTRFGSPYXCGMR-SDPRXREBSA-N rubixanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)/C)=C(C)C1 ABTRFGSPYXCGMR-SDPRXREBSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 1
- 235000004239 secoisolariciresinol Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 150000003436 stilbenoids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000008603 tangeritin Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003535 tetraterpenes Chemical class 0.000 description 1
- 235000009657 tetraterpenes Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- ZIUDAKDLOLDEGU-UHFFFAOYSA-N trans-Phytofluen Natural products CC(C)=CCCC(C)CCCC(C)CC=CC(C)=CC=CC=C(C)C=CCC(C)CCCC(C)CCC=C(C)C ZIUDAKDLOLDEGU-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 235000011557 tyrosol esters Nutrition 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000021470 vitamin B5 (pantothenic acid) Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000008964 vulgaxanthin Nutrition 0.000 description 1
- 229930185155 vulgaxanthin Natural products 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/61—Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J15/00—Feeding-tubes for therapeutic purposes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及低热量、高蛋白质营养组合物及其应用方法。具体而言,本发明提供了具有减少量的热量和高量的蛋白质的营养组合物以及制备和应用该营养组合物的方法。营养组合物可以含有处理的全食物组分、高量的蛋白质和减少量的热量,以便给患者提供pH平衡的配方,所述的配方含有除了必需的大量营养素和微量营养素之外的食物生物活性益处,而不提供过量的能量。本发明还提供了给需要改善骨、肌肉、神经、免疫和/或整体健康的患者施用该营养组合物的方法。
Description
本申请为2011年6月28日提交的发明名称为“低热量、高蛋白质营养组合物及其应用方法”的PCT申请PCT/US2011/042148的分案申请,所述PCT申请进入中国国家阶段日期为2012年12月28日,申请号为201180032248.0。
技术领域
本发明提供了含有全食物(wholefoods)的营养组合物。本发明还提供了制备和应用该营养组合物的方法。
发明内容
在通用实施方案中,本公开提供了低热量、完全每日喂养的含有处理的全食物组分、维生素或矿物质源和蛋白质源(其提供来自蛋白质的能量占配方总能量的约18%至约35%)的管饲配方。
在一个实施方案中,处理的全食物组分可以选自处理的水果、处理的蔬菜、处理的肉、处理的谷物或其组合。在另一个实施方案中,全食物组分没有处理。
在一个实施方案中,管饲配方具有约0.5至约0.8kcal/mL的热密度。
在一个实施方案中,蛋白质选自包括基于乳制品的蛋白质、基于植物的蛋白质、基于动物的蛋白质、人工蛋白质或其组合。基于乳制品的蛋白质可以选自酪蛋白、酪蛋白酸盐、酪蛋白水解物、乳清、乳清水解物、乳清浓缩物、乳清分离物、乳蛋白质浓缩物、乳蛋白质分离物或其组合。基于植物的蛋白质包括例如大豆蛋白质(例如所有形式,包括浓缩物和分离物)、豌豆蛋白质(例如所有形式,包括浓缩物和分离物)、油菜蛋白质(例如所有形式,包括浓缩物和分离物),其它可商购的植物蛋白质是小麦和分级的(fractionated)小麦蛋白质、玉米和其部分(fractions)包括玉米醇溶蛋白质、粳米、燕麦、马铃薯、花生以及衍生自豆、乔麦、小扁豆、干豆(pulses)的任何蛋白质、单细胞蛋白质或其组合。基于动物的蛋白质可以选自牛肉、家禽肉、鱼肉、羊肉、海鲜或其组合。
在一个实施方案中,管饲配方包含益生元,所述的益生元选自阿拉伯胶、α-葡聚糖、阿拉伯半乳聚糖、β-葡聚糖、右旋糖酐、低聚果糖(fructooligosaccharides)、岩藻糖基乳糖(fucosyllactose)、低聚半乳糖(galactooligosaccharides)、半乳甘露聚糖、低聚龙胆糖(gentiooligosaccharides)、低聚葡萄糖(glucooligosaccharides)、瓜尔胶、菊糖、低聚异麦芽糖(isomaltooligosaccharides)、乳新四糖(lactoneotetraose)、乳蔗糖(lactosucrose)、乳果糖(lactulose)、果聚糖、麦芽糊精、乳(milk)寡糖、部分水解的瓜尔胶、果胶低聚糖(pecticoligosaccharides)、抗性淀粉、回生淀粉(retrogradedstarch)、唾液酸低聚糖(sialooligosaccharides)、唾液酰基乳糖(sialyllactose)、大豆低聚糖、糖醇、低聚木糖(xylooligosaccharides)、它们的水解物或其组合。
在一个实施方案中,管饲配方包含益生菌,所述的益生菌选自气球菌属(Aerococcus)、曲霉菌属(Aspergillus)、拟杆菌属(Bacteroides)、双歧杆菌属(Bifidobacterium)、念珠菌属(Candida)、梭菌属(Clostridium)、德巴利酵母属(Debaromyces)、肠球菌属(Enterococcus)、梭杆菌属(Fusobacterium)、乳杆菌属(Lactobacillus)、乳球菌属(Lactococcus)、明串珠菌属(Leuconostoc)、蜜蜂球菌属(Melissococcus)、微球菌属(Micrococcus)、毛霉菌属(Mucor)、酒球菌属(Oenococcus)、片球菌属(Pediococcus)、青霉属(Penicillium)、消化链球菌属(Peptostrepococcus)、毕赤酵母属(Pichia)、丙酸杆菌属(Propionibacterium)、Pseudocatenulatum、根霉菌属(Rhizopus)、酵母菌属(Saccharomyces)、葡萄球菌属(Staphylococcus)、链球菌属(Streptococcus)、球拟酵母属(Torulopsis)、魏斯氏菌属(Weissella)或其组合。
在一个实施方案中,管饲配方包含氨基酸,所述的氨基酸选自丙氨酸、精氨酸、天冬酰胺、天冬氨酸(aspartate)、瓜氨酸、半胱氨酸、谷氨酸(glutamate)、谷氨酰胺、甘氨酸、组氨酸、羟基脯氨酸、羟基丝氨酸、羟基酪氨酸、羟基赖氨酸、异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸或其组合。
在一个实施方案中,管饲配方包含鱼油的脂肪酸组分,其选自二十二碳六烯酸(“DHA”)、二十碳五烯酸(“EPA”)或其组合。DHA和EPA还可以衍生自鳞虾、藻类、改良的植物、亚麻子、胡桃等。某些脂肪酸(例如18:4脂肪酸)还可以易于转化为DHA和/或EPA。
在一个实施方案中,管饲配方包含至少一种植物营养物。在一个实施方案中,植物营养物选自类黄酮、同源的酚化合物(alliedphenoliccompounds)、多酚化合物、类萜、生物碱、含硫化合物或其组合。植物营养物可以是例如类胡萝卜素、植物甾醇、槲皮素、姜黄素或柠檬苦素或其组合。
在一个实施方案中,管饲配方包含核苷酸。该核苷酸可以是脱氧核糖核酸的亚基、核糖核酸的亚基、聚合脱氧核糖核酸、聚合核糖核酸或其组合。
在一个实施方案中,管饲配方包含抗氧化剂,所述的抗氧化剂选自虾青素、类葫萝卜素、辅酶Q10(“CoQ10”)、类黄酮、谷胱甘肽Goji(枸杞(wolfberry))、橙皮苷、lactowolfberry、木酚素、叶黄素、番茄红素、多酚、硒、维生素A、维生素C、维生素E、玉米黄质或其组合。
在一个实施方案中,维生素选自维生素A和前体,例如β胡萝卜素、维生素B1(硫胺素)、维生素B2(核黄素)、维生素B3(烟酸或烟酰胺)、维生素B5(泛酸)、维生素B6(吡多辛、吡哆醛或吡哆胺或盐酸吡多辛)、维生素B7(生物素)、维生素B9(叶酸)和维生素B12(多种钴胺;通常是维生素补充剂中的氰基钴胺)、维生素C、维生素D、维生素E、维生素K、K1和K2(即MK-4、MK-7)、叶酸、生物素、胆碱或其组合。
在一个实施方案中,矿物质选自硼、钙、铬、铜、碘、铁、镁、锰、钼、镍、磷、钾、硒、硅、锡、钒、锌的多种盐或其组合。
在另一个实施方案中,本公开提供了制备完全每日喂养管饲组合物的方法。该方法包括组合全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的量的来自蛋白质的能量),以形成混合物。该方法进一步包括处理混合物,以形成完全每日喂养的管饲组合物。处理可以包括混合或液化,或者全食物组分可以是植物化学物和/或核苷酸源。
在一个实施方案中,全食物组分可以选自水果、蔬菜、肉、谷物、草、香料、矫味剂或其组合。
在另一个实施方案中,本公开提供了改善管饲儿科患者的全部健康的方法,所述的患者患有潜在的医学病症,包括那些长期管饲患者。该方法包括给患有潜在医学病症的管饲儿科患者施用低热量、完全每日喂养的管饲配方,所述的配方具有处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。潜在的医学病症可以是脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、免疫缺陷、低骨密度、压力性溃疡、慢性创伤或其组合。
在另一个实施方案中,本公开提供了在长期管饲儿科患者中治疗和/或预防肥胖或最小化过度的脂肪量堆积的方法。该方法包括给肥胖或存在变肥风险的管饲儿科患者施用低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,本公开提供了促进管饲儿科患者正常生长的方法。该方法包括给需要的管饲儿科患者施用低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,本公开提供了维持管饲儿科患者代谢体内平衡的方法。该方法包括给需要的患者施用低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,本公开提供了改善抗癫痫药物治疗的管饲儿科患者骨健康的方法。该方法包括给抗癫痫药物治疗的管饲儿科患者施用低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素D源(其提供每升配方或每600kcal至少500IU的维生素D)和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。维生素D应当是以每升产品或每600kcal的总组合物施用的。
在另一个实施方案中,提供了减少管饲儿科患者医疗费用的方法。该方法包括提供低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其每天提供约18%至约35%的来自蛋白质的能量)。该方法进一步包括给患有需要医治的潜在的医学病症的管饲儿科患者施用管饲配方。施用管饲配方改善了患者的潜在的医学病症。在一个实施方案中,潜在的医学病症选自脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、延长的卧床休养、固定、截瘫/四肢瘫痪、免疫缺陷、低骨密度、压力性溃疡、慢性创伤或其组合。
在另一个实施方案中,提供了改善儿童的全部健康的方法。该方法包括给儿童施用管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供每天每kg体重约1.6至约3.6g蛋白质),其中配方给儿童每天提供约900至约1,100kcal。
在一个实施方案中,蛋白质源提供每kg体重约1.8g蛋白质。蛋白质源还可以提供每kg体重约3.5g蛋白质。配方可以给儿童每天提供约1,000kcal。
在另一个实施方案中,提供了改善青春期前的青少年的全部健康的方法。该方法包括给青春期前的青少年施用管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供每天每kg体重约1.25至约2.75g蛋白质),其中配方给青春期前的青少年每天提供约1,100至约1,300kcal。
在一个实施方案中,蛋白质源提供每kg体重约1.35g蛋白质。蛋白质源还可以提供每kg体重约2.63g蛋白质。配方可以给青春期前的青少年每天提供约1,200kcal。
本公开的优点是提供改善的管饲配方。
本公开的另一个优点是提供包含全食物的改善的营养组合物。
本公开的另一个优点是提供促进骨健康的营养组合物。
本公开的另一个优点是提供维持瘦体重和最小化过量脂肪堆积的营养组合物。
本公开的另一个优点是提供维持代谢体内平衡的营养组合物。
本公开的另一个优点是提供治疗和/或预防压力性溃疡的营养组合物。
本公开的另一个优点是提供维持肠健康的营养组合物。
本公开的另一个优点是提供改善和/或预防管饲喂养的喂养不耐的营养组合物。
本公开的一个优点是提供改善患有脑性瘫痪和/或其它神经肌肉障碍的患者的全部健康的营养组合物。
本文描述了其它特征和优点,并且根据下列详述和附图将变得显而易见。
详述
本文所用的“约”应该理解为表示数值的范围。而且,本文所有数值范围应该理解为包括范围内的所有整数、全部(whole)或分数。
本文所用的术语“氨基酸”应当理解为包括一种或多种氨基酸。氨基酸可以是例如丙氨酸、精氨酸、天冬酰胺、天冬氨酸(aspartate)、瓜氨酸、半胱氨酸、谷氨酸(glutamate)、谷氨酰胺、甘氨酸、组氨酸、羟基脯氨酸、羟基丝氨酸、羟基酪氨酸、羟基赖氨酸、异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸或其组合。
本文所用的“动物”包括但不限于哺乳动物,其包括但不限于啮齿动物,水生哺乳动物,家养动物如狗和猫,耕作动物如绵羊、猪、牛和马,以及人。其中当应用术语“动物”或“哺乳动物”或它们的复数时,应当理解为它还适用于能够由传代(bythecontextofpassage)显示或预期显示效果的任何动物。
本文所用的术语“抗氧化剂”应当理解为包括任何一种或多种不同的物质,例如β胡萝卜素(维生素A前体)、维生素C、维生素E和硒,其抑制活性氧类别(“ROS”)和其它基团和非基团种类引发的氧化或反应。此外,抗氧化剂是能够减缓或防治其它分子氧化的分子。抗氧化剂的非限制性实例包括虾青素、类葫萝卜素、辅酶Q10(“CoQ10”)、类黄酮、谷胱甘肽Goji(枸杞)、橙皮苷、lactowolfberry、木酚素、叶黄素、番茄红素、多酚、硒、维生素A、维生素C、维生素E、玉米黄质或其组合。
本文所用的“完全营养”包括营养品和组合物,其含有足够类型和水平的大量营养素(蛋白质、脂肪和碳水化合物)和微量营养素,足以成为所施用的动物的唯一营养源。患者从此类完全营养组合物中接受100%的他们的营养需求。
本文所用的“有效量”是预防缺乏、治疗个体的疾病或医学病症,或更普遍地,减少症状、控制疾病进程或给个体提供营养、生理或医学益处的量。治疗可以是患者或医生相关的。
尽管本文经常所用的术语“个体”和“患者”是指人,但是本发明没有被如此限制。因此,术语“个体”和“患者”是指具有医学病症或存在医学病症风险可以从该治疗中受益的任何动物、哺乳动物或人。
本文所用的鱼油的脂肪酸组分的非限制性实例包括二十二碳六烯酸(“DHA”)和二十碳五烯酸(“EPA”)。DHA和EPA的其它来源包括鳞虾、ω-3的植物源、亚麻子、胡桃和藻类。
本文所用的“食物级微生物”是指所用的并且在食物应用中通常被认为是安全的微生物。
本文所用的“不完全营养”包括营养品或组合物,其不含有足够水平的大量营养素(蛋白质、脂肪和碳水化合物)和微量营养素,足以成为所施用的动物的唯一营养源。部分或不完全营养组合物可以用作营养补充剂。
本文所用的“长期施用”优选是连续施用超过6周。或者,本文所用的“短期施用”是连续施用小于6周。
本文所用的“哺乳动物”包括但不限于啮齿动物,水生哺乳动物,家养动物如狗和猫,耕作动物如绵羊、猪、牛和马,以及人。其中当应用术语“哺乳动物”时,应当理解为它还适用于能够由哺乳动物显示或预期显示效果的其它动物。
术语“微生物”是指包括细菌、酵母和/或真菌、含有微生物的细胞生长培养基或微生物在其中培养的细胞生长培养基。
本文所用的术语“矿物质”应当理解为包括硼、钙、铬、铜、碘、铁、镁、锰、钼、镍、磷、钾、硒、硅、锡、钒、锌或其组合。
本文所用的“无复制的”微生物是指可以通过标准平板培养法检测的无活细胞和/或菌落形成单位。这类标准平板培养法在微生物学书中有概述:JamesMonroeJay等人,Modernfoodmicrobiology,第7版,SpringerScience,NewYork,N.Y.p.790(2005)。通常,如下显示没有活细胞:琼脂平板上没有可见的菌落或用不同浓度细菌制剂(无复制样品)接种并且在适宜条件下温育(需氧和/或厌氧气氛下至少24小时)后液体生长培养基中浊度没有增加。例如,双歧杆菌如长双歧杆菌(Bifidobacteriumlongum)、乳双歧杆菌(Bifidobacteriumlactis)和短双歧杆菌(Bifidobacteriumbreve)或乳杆菌属(lactobacilli)如副干酪乳杆菌(Lactobacillusparacasei)或鼠李糖乳杆菌(Lactobacillusrhamnosus),可以通过热处理,特别是低温/长时间热处理制成无复制。
本文所用的“正常的骨生长”是指儿童和青少年骨通过塑造成型的过程,其在一个位置形成新骨并且在相同骨里面从另一个位置除去旧骨。该过程使得个体骨正常生长并且移入适合空间。在儿童骨生长期,由于再吸收(破骨过程)发生在骨里面,而新骨形成发生在它的外部(骨膜)表面。在青春期,由于形成可以发生在外部和内部(骨内膜)表面,因此骨增厚。重建过程贯穿整个生命,并且当骨到达顶峰重量(通常刚二十几岁)时成为主要过程。在重建中,骨小粱表面上或皮质内部中的少量骨被除去,然后在相同位置置换。重建过程不改变骨的形状,但是它对骨健康是至关重要的。塑造和重建持续贯穿整个生命,以致大多数成年人骨骼每隔约10年被置换。然而重建在早期成年期占优势,塑造可以特别是在骨退化时出现。
本文所用的“核苷酸”应当理解为脱氧核糖核酸(“DNA”)、核糖核酸(“RNA”)、聚合RNA、聚合DNA或其组合的亚基。它是含氮碱基、磷酸分子和糖分子(在DNA中为脱氧核糖,并且在RNA中为核糖)组成的有机化合物。单独核苷酸单体(单一单元)连接在一起形成聚合物或长链。饮食补充剂特别提供外源性核苷酸。外源性核苷酸可以是单体形式,例如5’-腺苷一磷酸(“5’-AMP”)、5’-鸟苷一磷酸(“5’-GMP”)、5’-胞苷一磷酸(“5’-CMP”)、5’-尿苷一磷酸(“5’-UMP”)、5’-肌苷一磷酸(“5’-IMP”),5’-胸苷一磷酸(“5’-TMP”)或其组合。外源性核苷酸还可以是聚合物形式,例如完整的RNA。存在多种来源的聚合物形式,例如酵母RNA。
本文所用的“营养品”或“营养组合物”应当理解为包括任意数量的任选的其它成分,包括常规食品添加剂(合成的或天然的),例如一种或多种酸化剂、其它增稠剂、缓冲剂或pH调节剂、螯合剂、着色剂、乳化剂、赋形剂、矫味剂、矿物质、渗透剂、可药用载体、防腐剂、稳定剂、糖、甜味剂、组织形成剂和/或维生素。任选的成分可以以任何适合的量添加。营养品或组合物可以是完全营养的来源或者是不完全营养的来源。
本文所用的术语“患者”应该理解为包括动物,特别是哺乳动物,并且更特别是接受或预期接受治疗的人,如本文所定义的。
本文所用的“植物化学物”或“植物营养物”是很多食物中存在的非营养化合物。植物化学物是具有除基本营养之外的健康益处的功能性食物,是源于植物来源的促进健康的化合物,并且可以是天然的或纯化的。“植物化学物”和“植物营养物”是指由植物产生的任何化学品,其赋予应用者一种或多种健康益处。植物化学物和植物营养物的非限制性实例包括下面那些:
i)酚化合物,包括单酚(例如芹菜脑、鼠尾草酚、香芹酚、莳萝油脑(dillapiole)、rosemarinol);类黄酮(多酚),包括黄酮醇(例如槲皮素、姜酚、山柰酚、杨梅黄酮、芦丁、异鼠李亭)、黄烷酮(例如橙皮苷、柚苷配基、水飞蓟宾、圣草酚)、黄酮(例如芹菜素、柑橘黄酮、四羟黄酮)、黄烷-3-醇(例如儿茶素、(+)-儿茶素、(+)-棓儿茶素、(-)-表儿茶素、(-)-表棓儿茶素、(-)-表棓儿茶素棓酸酯(EGCG)、(-)-表儿茶素3-棓酸酯、茶黄素、茶黄素-3-棓酸酯、茶黄素-3’-棓酸酯、茶黄素-3,3’-二棓酸酯、茶红素(thearubigins))、花色素苷(flavonals)和花色素(例如花葵素、芍药素、矢车菊色素、翠雀色素、锦葵色素、矮牵牛素)、异黄酮(植物雌激素)(例如黄豆苷元(芒柄花黄素)、染料木黄酮(鹰嘴豆素A)、黄豆黄素)、二氢黄酮醇、查耳酮、配糖(coumestans)(植物雌激素)和考迈斯托醇;酚酸(例如鞣花酸、棓酸、鞣酸、香兰素、姜黄素);羟基肉桂酸(例如咖啡酸、绿原酸、肉桂酸、阿魏酸、香豆素);木酚素(植物雌激素)、水飞蓟素、Secoisolariciresinol、松脂酚和落叶松树脂醇);酪醇酯(例如酪醇、羟基酪醇、Oleocanthal、齐墩果苷);stilbenoids(例如白藜芦醇、蝶芪、四羟反式茋(piceatannol))和punicalagins;
ii)萜(类异戊二烯),包括类胡萝卜素(类四萜)、包括胡萝卜素(例如α-胡萝卜素、β-胡萝卜素、γ-胡萝卜素、δ-胡萝卜素、番茄红素、链孢红素、六氢番茄红素、八氢番茄红素)和叶黄素(例如斑蝥黄、隐黄质、玉米黄质、虾青素、叶黄素、玉红黄质);单帖(例如烯、紫苏子醇);皂草苷;脂质,包括植物甾醇(例如菜油甾醇、β-谷甾醇、γ-谷甾醇、豆甾醇)、生育酚(维生素E)以及ω-3、6和9脂肪酸(例如γ-亚麻酸);三萜系化合物(例如齐墩果酸、熊果酸、桦木酸、moronicacid);
iii)甜菜红,包括β-花青素(例如甜菜苷、异甜菜苷、probetanin、新甜菜苷(neobetanin));和甜菜黄素(非糖苷型)(例如梨果仙人掌黄素和仙人掌黄素(vulgaxanthin));
iv)有机硫化物,包括dithiolthiones(异硫氰酸盐)(例如sulphoraphane);和Thiosulphonates(葱属化合物)(例如烯丙基甲基三硫和二烯丙基硫醚)、吲哚化合物、硫代葡萄糖酸盐(glucosinolates),包括例如吲哚-3-甲醇;萝卜硫烷;3,3’-二吲哚基甲烷;黑芥子苷;蒜素;蒜氨酸;异硫氰酸丙烯酯;胡椒碱;顺式-丙硫醛-S-氧化物;
v)蛋白质抑制剂,包括例如蛋白酶抑制剂;
vi)其它有机酸,包括草酸、植酸(六磷酸肌醇);酒石酸;和漆树酸;或者
vii)其组合。
除非上下文明确说明,本公开和附属的权利要求中所用的单数形式“一个”、“一种”包括复数指示物。因此,提及的“多肽”包括两种或多种多肽的混合物等。
本文所用的“益生元”是选择性促进有益菌生长或抑制肠道中致病菌生长或粘膜吸附的食物。它们没有在胃和/或高位肠中被灭活,也没有吸附在摄入益生元的人的胃肠道中,但是它们被胃肠道微生物区系和/或被益生菌发酵。益生元是例如GlennR.Gibson和MarcelB.Roberfroid,DietaryModulationoftheHumanColonicMicrobiota:IntroducingtheConceptofprebiotics(膳食调节人结肠微生物区系:引入益生元概念),J.Nutr.1995125:1401-1412中所定义的。益生元的非限制性实例包括阿拉伯胶、α-葡聚糖、阿拉伯半乳聚糖、β-葡聚糖、右旋糖酐、低聚果糖、岩藻糖基乳糖、低聚半乳糖、半乳甘露聚糖、低聚龙胆糖、低聚葡萄糖、瓜尔胶、菊糖、低聚异麦芽糖、乳新四糖、乳蔗糖、乳果糖、果聚糖、麦芽糊精、乳寡糖、部分水解的瓜尔胶、果胶低聚糖、抗性淀粉、回生淀粉、唾液酸低聚糖、唾液酰基乳糖、大豆低聚糖、糖醇、低聚木糖或它们的水解物或其组合。
本文所用的益生菌微生物(下文称为“益生菌”)是食物级的微生物(活的,包括半活的或衰落的,和/或无复制的)、代谢产物、微生物细胞制剂或微生物细胞的组分,当适当施用时其能为宿主提供健康益处,更特别地,它们通过改善肠道微生物平衡有益地影响宿主,对宿主的健康或良好状态产生影响。参见SalminenS,OuwehandA.BennoY.等人,Probiotics:howshouldtheybedefined?(益生菌:如何定义它们),TrendsFoodSci.Technol.1999:10,107-10。通常,认为这些微生物抑制或影响肠道中致病菌的生长和/或代谢。益生菌还可以激活宿主的免疫功能。为此,存在多种不同的方法将益生菌引入食品中。益生菌的非限制性实例包括气球菌属、曲霉菌属、拟杆菌属、双歧杆菌属、念珠菌属、梭菌属、德巴利酵母属、肠球菌属、梭杆菌属、乳杆菌属、乳球菌属、明串珠菌属、蜜蜂球菌属、微球菌属、毛霉菌属、酒球菌属、片球菌属、青霉属、消化链球菌属、毕赤酵母属、丙酸杆菌属、Pseudocatenulatum、根霉菌属、酵母菌属、葡萄球菌属、链球菌属、球拟酵母属、魏斯氏菌属或其组合。
本文所用的“处理的全食物”是由其天然或制备的状态改良的全食物,并且其处于它可以放入管饲配方中的状态。
本文所用的术语“蛋白质”、“肽”、“寡肽”或“多肽”应当理解为表示包含单个氨基酸(单体)、通过肽键连接在一起的两个或多个氨基酸(二肽、三肽或多肽)、胶原、前体、同系物、类似物、模拟物、盐、前药、代谢物或其片段或其组合的任何组合物。为了清楚,除非具体说明,否则任何上述术语可互换应用。应当理解的是多肽(或肽或蛋白质或寡肽)常常含有除通常称为20种天然存在的氨基酸的20种氨基酸以外的氨基酸,并且在给出的多肽中很多氨基酸(包括末端氨基酸)可以通过天然过程(例如糖基化和其它翻译后修饰)或通过本领域熟知的化学修饰技术进行修饰。本发明多肽中可以存在的已知的修饰包括但不限于乙酰化、酰化、ADP-核糖基化、酰胺化、类黄酮或血红素部分的共价连接、多核苷酸或多核苷酸衍生物的共价连接、脂质或脂质衍生物的共价连接、磷脂酰肌醇的共价连接、交联、环化、二硫键形成、脱甲基化、共价交联的形成、胱氨酸的形成、焦谷氨酸的形成、甲酰化、γ-羧基化、糖化、糖基化、糖基磷脂酰肌醇(“GPI”)膜锚着点形成、羟基化、碘化、甲基化、肉豆蔻酰化、氧化、蛋白酶解加工、磷酸化、异戊烯化、外消旋化、硒酰化(selenoylation)、硫酸化、转移-RNA介导的氨基酸与多肽的加成,例如精氨酰化以及遍在蛋白化。术语“蛋白质”还包括“人工蛋白质”,其表示线性或非线性多肽,由交替重复的肽组成。
蛋白质的非限制性实例包括基于乳制品的蛋白质、基于植物的蛋白质、基于动物的蛋白质和人工蛋白质。基于乳制品的蛋白质可以选自酪蛋白、酪蛋白酸盐、酪蛋白水解物、乳清、乳清水解物、乳清浓缩物、乳清分离物、乳蛋白质浓缩物、乳蛋白质分离物或其组合。基于植物的蛋白质包括例如大豆蛋白质(例如所有形式,包括浓缩物和分离物)、豌豆蛋白质(例如所有形式,包括浓缩物和分离物)、油菜蛋白质(例如所有形式,包括浓缩物和分离物),其它可商购的植物蛋白质是小麦和分级的小麦蛋白质、玉米和其部分包括玉米醇溶蛋白质、粳米、燕麦、马铃薯、花生以及衍生自豆、乔麦、小扁豆、干豆的任何蛋白质、单细胞蛋白质或其组合。基于动物的蛋白质可以选自牛肉、家禽肉、鱼肉、羊肉、海鲜或其组合。
本申请书中包括的所有剂量范围旨在包括所述范围内包括的所有数值,整数或分数。
本文所用的“合生素”是指含有益生元和益生菌的补充剂,它们一起起作用改善肠道的微生物区系。
本文所用的术语“治疗”和“缓解”包括预防性或防止性治疗(预防和/或延缓目标病理学病症或障碍的发展)和治愈、治疗或改善疾病的治疗,包括治愈、延缓、减轻诊断的病理学病症或障碍的症状和/或中断其进程的治疗措施;和治疗存在感染疾病风险或怀疑已经染病的患者,以及治疗患病或已经诊断为患有疾病或医学病症的患者。术语不必须表示个体被治疗直至完全恢复。术语“治疗”还表示维持和/或促进个体的健康,所述的个体尽管没有患病,但是他们易于发展为不健康的病症,例如氮失调或肌肉损耗。术语“治疗”和“缓解”还旨在包括增强或在其它方面提高一种或多种主要的预防或治疗措施。术语“治疗”和“缓解”进一步旨在包括疾病或病症的膳食管理或者预防或防止疾病或病症的膳食管理。
本文所用的“管饲”是施用于动物的胃肠系统而非通过口服施用的完全或不完全营养品或组合物,包括但不限于鼻胃管、口胃管、胃管、空肠造口术置管(J-管)、经皮内镜胃造口术(“PEG”)、孔、例如提供到达胃、空肠的通路的胸壁孔和其它适宜的孔。
本文所用的术语“维生素”应当理解为包括少量对机体正常生长和活动所必需的并且天然地从植物或动物食物中获得的或合成制得的任何多种脂溶的或水溶的有机物(非限制性实例包括维生素A、维生素B1(硫胺素)、维生素B2(核黄素)、维生素B3(烟酸或烟酰胺)、维生素B5(泛酸)、维生素B6(吡多辛、吡哆醛或吡哆胺或盐酸吡多辛)、维生素B7(生物素)、维生素B9(叶酸)和维生素B12(多种钴胺;通常为维生素补充剂中的氰基钴胺)、维生素C、维生素D、维生素E、维生素K、K1和K2(即MK-4、MK-7)、叶酸和生物素),维生素原、衍生物、类似物。
本文所用的“全食物”或“真实的食物”应当理解为表示当相对于任何减少组分的食物,该食物是其天然或制备的状态时,在日常饮食中个体通常摄入的食物。例如,全食物可以包括任何已知的水果、蔬菜、谷物、肉或蛋白质源。
本文所用的“动物化学物”表示具有除基本营养之外的健康益处并且为促进健康的化合物的功能食物,其存在于动物源中。
不活动的或长时间喂食一种显著量的单一饮食的患者易患可能由于饮食中缺乏多种或合适的营养物引起的代谢紊乱。例如,长期管饲患者可能患有这类紊乱。尽管患者的基本营养需求可以通过管饲来满足,但是没有优化目前的管饲配方,以维持长时间内患者健康。
接受长期管饲的患者通常保持单一饮食来源达数周、数月或甚至数年。这类长期管饲患者可能患有多种健康并发症,包括例如骨、肌肉、神经、胃肠道和免疫健康障碍。患有这些类型的慢性疾病和并发症的此类长期管饲患者的营养需求当然不同于需要短期管饲的那些患者。
例如,脑性瘫痪是慢性、非进行性运动残疾,其由早期脑发育损伤导致。通常脑性瘫痪的特征在于运动协调和肌紧张功能障碍。由于这些患者通常坐轮椅或离床活动很困难,因此他们的能量需求显著低于健康儿童的需求,但是他们的蛋白质需求常常更高,以支持生长、修复和合成代谢功能。这些儿童常常需要专有的管饲。尽管长期管饲患者的喂养需求不同于短期管饲患者,但是技术人员认为本发明组合物可以用于短期或长期管饲患者,以及接受补充营养的患者。
在另一个实例中,虽然机体血液pH主要通过肾和肺的调节来得以很好地随时间维持,但是膳食摄入可以显著影响机体的酸/碱平衡。住院的、送进专门机构的(institutionalized)和恢复的患者可能增加患有由衰弱的肾和/或肺功能导致的代谢紊乱的风险。因此,膳食的酸-碱可能性在维持患者健康(包括肌骨骼和免疫健康)中变得越来越重要。
摄入并且代谢后,食物可以分为产生更酸的净值(net)或更碱。相关的人类摄入数据表明更高的水果和蔬菜的膳食提供净碱性环境,有助于维持代谢体内平衡。相反,已经发现产生酸的膳食对肌骨骼健康产生不利影响。通过膳食修饰校正低级代谢性酸中毒有助于维持骨骼肌质量和肌骨骼状态,并且改善患有多种病理学病症(包括例如肌肉损耗)的患者健康。调节完全营养配方中的磷(P)、钠(Na)、镁(Mg)、钾(K)和钙(Ca)可以以这种方式增加净碱的产生。
由于长期管饲患者在他们的食物来源中缺少多样性,因此他们对成酸性膳食的效应特别敏感。尽管肾能有效中和酸,但是一般认为长期暴露于很高的酸会损害肾中和酸的能力,从而可能出现潜在的损伤。因此,碱性化合物用于中和这些膳食的酸(在肌肉的情况中,谷氨酰胺可以用作缓冲剂),所述的碱性化合物包括但不限于钙。机体内最易获得的钙来源是骨。一种理论是高酸性膳食可能促使骨丢失,因为机体动用了储存的钙,以缓冲代谢的酸。这种假说是低酸性膳食可能产生多种益处,其包括减弱骨和肌肉丢失以及维持肾健康。参见Wachman,A.等人,DietandOsteoporosis(膳食和骨质疏松),Lancet,1:958-959(1968);还参见FrassettoL等人,PotassiumBicarbonateReducesUrinaryNitrogenExcretioninPostmenopausalWomen(碳酸氢钾减少绝经妇女的尿氮排泄),J.Clin.Endocrinol.Metab.,82:254-259(1997)。
事实上,骨折在患有多种原因引起的四肢痉挛的儿童中是一个重要问题。此外,很多患有脑性瘫痪的儿童服用多种抗惊厥药用于控制癫痫发作,并且维生素D和钙代谢的变化与某些抗惊厥药的应用相关。参见Hahn,T.J.等人,EffectofChronicAnticonvulsantTherapyonSerum25-HydroxycalciferolLevelsinAdults(慢性抗惊厥治疗对成年人的血清25-羟基麦角钙化固醇水平的影响),TheNewEnglandJ.ofMed.,第900-904页(1972年11月2日)。还参见Hunter,J.等人,AlteredCalciumMetabolisminEpilepticChildrenonAnticonvulsants(服用抗癫痫药的癫痫儿童中改变的钙代谢),BritishMedicalJournal,第202-204页(1971年10月23日)。还参见Hahn,T.J.等人,Phenobarbital-InducedAlterationsinvitaminDMetabolism(苯巴比妥诱导的维生素D代谢的改变),J.ofClinicalInvestigation,第51卷,第741-748页(1972)。尽管抗惊厥药对维生素D状态的影响没有完全清楚,但是显然不能走动的儿童增加了骨折风险。
研究表明控制癫痫发作的药物(例如苯巴比妥和大仑丁)可以改变维生素D的代谢和循环半衰期。研究还表明服用至少两种抗癫痫药物的患者增加他们的维生素D摄入至每天约25μg(1,000IU),以维持他们的血清25(OH)D水平在25至45ng/mL(62.5至112.5nmol/升)的中间正常范围内,所述的患者是送进专门机构的,因此无法通过暴露于日光获得大多数他们的维生素D需求。人们认为应当预防与抗癫痫药物相关的骨软化和维生素D缺乏。
在另一个实例中,患有脑性瘫痪和神经肌肉障碍的患者(特别是儿童)还常常处于发生压力性溃疡或慢性创伤的风险,并且因此需要特别的膳食。易患慢性创伤的个体包括例如延长固定、被束缚在床和椅子和/或经历失禁的那些人,经历蛋白能量营养不良、免疫抑制的那些人,或患有神经、创伤或晚期疾病的那些人,或者患有循环或感觉缺陷的那些人。参见AgencyforHealthCarePolicyandResearch,1992,1994。接受适当的营养在预防和治疗此类慢性创伤中发挥重要作用。
例如,特别的营养物例如蛋白质、维生素A、维生素C、维生素E、锌和精氨酸在降低发生压力性溃疡风险中发挥作用,特别是如果怀疑缺乏。适当的水合作用在降低发生压力性溃疡风险中发挥显著作用。事实上,已经报道当相比对照组,压力性溃疡发病率在接受额外的蛋白质、精氨酸、维生素C和锌的组中更低(13%对72%)。参见Neander等人,Aspecificnutritionalsupplementreducesincidenceofpressureulcerinelderlypeople(特别的营养补充剂降低老年人的压力性溃疡的发病率),NumicoResearch,www.numico-research.com。
一旦发生慢性创伤或压力性溃疡,多种营养物在愈合中发挥重要作用,特别的营养物对病程的不同阶段存在影响。例如,下表1说明了影响创伤愈合不同阶段的主要营养物。如表1所示,某些维生素、矿物质和氨基酸存在于创伤愈合的不同阶段。
表1
预防压力性溃疡发生或进程还具有显著的健康经济含义。例如,对于压力性溃疡,溃疡后期的平均愈合时间更长,阶段III和阶段IV溃疡比阶段II需要显著更长的治疗。在UK疾病花费研究中,清楚地发现治疗费用随着压力性溃疡严重程度的增加而增加。参见BennettG等人,ThecostofpressureulcerintheUK(英国压力性溃疡的费用),AgeandAgeing,33:230-235(2004)。在另一个研究中,其显示阶段III和阶段IV的压力性溃疡治疗费用显著高于阶段II的压力性溃疡。参见XakellisGC等人,Thecostofhealingpressureulceracrossmultiplehealthcaresettings(交叉多种健康护理设备治愈压力性溃疡的费用),Adv.WoundCare,9:18-22(1996)。下表2中显示了这些显著的花费。
表2
更普遍地,对于管饲方案的儿科患者必须考虑很多费用。任何潜在的医学病症例如脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、免疫缺陷、低骨密度、慢性创伤等可能需要医院或其它医疗设施的医学护理。或者,很多这些病症还可能需要或提供补充医院随访、家庭医学护理。在任何一种情况下,管饲儿科患者的每日喂养可能包括管饲配方的费用、应用设备进行喂养的费用、进行喂养的卫生保健人员的费用、继发性健康监测设备的费用、医生随访的费用等。如上面关于压力性溃疡所讨论的,技术人员将意识到这些费用将随着潜在医学病症的严重程度的增加而增加。
因此,能够减少医疗随访的频率、住院期、喂养频率等以降低医疗护理费用,这对于儿科管饲患者或儿科患者的看护者而言是有利的。例如,已知儿科管饲患者通常经历正常生长的阻抗,因为患者通常久坐并且没有消耗非管饲膳食中发现的所有必需微量营养物和大量营养物。然而,例如如果给儿科患者施用提供所有必需微量营养物和大量营养物、更高量的蛋白质和更低热量的管饲配方,那么通过最小化过度的体重增长和/或过度的脂肪组织,管饲儿科患者可以能够获得改善的健康状况。因此,施用这类管饲可以降低与儿科患者病症相关的医疗费用以及降低营养组分(即蛋白质、纤维、微量营养物)的数量,这些物质通常“添加回”至稀释的1.0kcal配方。
基于以上讨论,长期管饲显然可能导致任何数量的原发或继发的健康关注。随着时间过去,如果提供给患有类似于上述那些的健康并发症的患者的管饲配方没有提供满足患者生理需求的所有膳食组分,那么累积日复一日的营养不足(或与天然的、多样且平衡的真实食物不同)可能对患者的健康产生渐增且有害的副作用,从而出现临床结果。
因此,本公开涉及营养品和组合物,其为这些患者提供足够体积、增加的蛋白质和更高水平的某些微量营养物和大量营养物,而不提供过量的能量。需要更高的蛋白质以支持合成代谢功能,维持瘦体重以及保持营养充足。低热量配方对于给极端限制在几乎没有机体活动性的患者递送更低热量是至关重要的,因为所提供的营养物必须维持体重增长而不会损害肌骨骼的健康。此外,其它膳食组分是以营养品和组合物提供的,其在一定条件下是必需的(例如核苷酸)或在其它方面对于患者的健康(例如植物化学物)是重要的。
营养组合物可以施用于患有先前存在的医学病症或处于发展成医学病症风险的个体。如上面讨论的,医学病症可以包括例如脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、免疫缺陷、低骨密度、压力性溃疡、慢性创伤或其组合。营养组合物可以是为任何哺乳动物(例如人或动物)而设计的配方。在一个实施方案中,营养组合物是管饲配方。
在一个实施方案中,当本发明营养组合物可以施用于任何患者群体时,营养组合物施用于患有或处于发展成任何上面提及的医学病症的儿科患者。对于不同类型的儿科患者,年龄范围可以在很宽范围内变化。本文所用的“幼儿”被认为是年龄范围为2至5岁的儿科患者。幼儿的体重范围可以从约30kg至约45kg。幼儿可以重约36kg。本文所用的“儿童”被认为是年龄范围为5至8岁的儿科患者。儿童的体重范围可以从约50kg至约60kg。儿童可以重约55kg。本文所用的“青春期前的青少年”被认为是年龄范围为8至13岁的儿科患者。青春期前的青少年的体重范围可以从约80kg至约85kg。青春期前的青少年可以重约88kg。
本发明的大量营养物分布的益处是支持生长,同时最小化过度的体重增长、中央型肥胖的堆积和相关的负面健康效应。中央型肥胖与胰岛素抗性和低度炎症有关,因此可能给低体力活动的成长的儿童提供低能量、高蛋白质膳食将预防胰岛素抗性,从而获得更有效的胰岛素活性和合成代谢。已经显示高蛋白质膳食调节合成代谢激素(例如生长激素)的分泌。参见Clarke等人,Effectofhigh-proteinfeedsupplementsonconcentrationsofgrowthhormone(“GH”),insulin-likegrowthfactor-I(“IGF-I”)andIGF-bindingprotein-3inplasmaandontheamountsofGHandmessengerRNAforGHinthepituitaryglandsofadultrams(高蛋白喂养补充剂对血浆中生长激素(“GH”)、胰岛素样生长因子-I(“IGF-I”)和IGF-结合蛋白-3的浓度以及GH和成年公羊垂体中GH的信使RNA的量的影响),J.Endocrinol.138(3):421-427(1993)。还参见J.R.Hunt等人,Dietaryproteinandcalciuminteracttoinfluencecalciumretention:acontrolledfeedingstudy(膳食蛋白质和钙相互作用影响钙保留:可控的喂养研究),Am.J.Clin.Nutr.89(5):1357-1365(2009)。还参见G.Blanchard等人,Rapidweightlosswithahigh-proteinlow-energydietallowstherecoveryofidealbodycompositionandinsulinsensitivityinobesedogs(高蛋白低能量膳食的快速体重减轻使得肥胖狗恢复理想身体组成和胰岛素敏感性),J.Nutr.134(8Suppl):2148S-2150S(2004)。
这些益处在快速生长过程中特别重要,因为已经显示生长激素轴与生命后期的慢性疾病相关。因此,调节生长激素轴(包括IGF-1)将有利于短期以及晚年患者的临床结果。这可以导致显著改善生活质量以及产生正面的健康经济结果。参见J.M.Kerver等人,Dietarypredictorsoftheinsulin-likegrowthfactorsysteminadolescentfemales:resultsfromtheDietaryInterventionStudyinChildren(DISC)(青少年女性中胰岛素样生长因子系统的膳食预测子:儿童中膳食干预研究(DISC)结果),Am.J.Clin.Nutr.91(3):643-650(2010)。
营养组合物可以以大丸剂或连续的管饲施用。在一个实施方案中,营养组合物作为大丸剂施用,因为它最大化对喂养时机的生理学应答。本方法为儿科群体提供了完全营养,因为在每次喂养时递送浓缩剂量的蛋白质。这种浓缩提供的蛋白质是增加血浆氨基酸(例如亮氨酸)、刺激蛋白质合成和获得净正蛋白质平衡所必需的。尽管有利于瘦体重和线性骨生长(有利于骨矿物质密度),但是需要这种喂养后的合成代谢状态以优化生长。机制与上面提及的增加血清亮氨酸以及合成代谢内分泌应答有关,包括刺激胰岛素-IGF-1-GH轴,导致增加摄取和生物利用肌骨骼发育的物质(从而导致内脏肥胖累积的降低)。在一个实施方案中,对于1至13岁的儿科患者,本发明营养组合物的完全喂养将为约1000mL。年龄超过13岁的儿童和成年人可以从这种配方中受益,但是应当评估热量需求以及大量-微量营养物需求,以保证营养的最佳递送。
生理学喂养还包括引入多种生长儿童的膳食。该想法包括类似于早餐、午餐、晚餐、零食模式的大丸剂喂养,其中所设计的肠内配方包括代表不同、混合、循环菜单膳食的多种食物组分。菜单循环中的多种食物可以通过引入人种的食物进一步多样化,同时通过不同的水果、蔬菜、草或香料增加产品的植物营养素分布。这种方案除了基本营养物之外合并了真实食物的益处,并且可以提供具有健康益处的植物和动物化学物的来源。这些益处包括但不限于强大的氧化性应激调节,导致降低胰岛素抗性,从而增加生物利用,导致有利于瘦体重和缓冲净酸分泌,产生最佳线性生长和有利于更高质量的骨量。
在一个实施方案中,本公开的管饲配方包括全食物或真实食物组分。全食物除了公认的大量营养物、维生素和矿物质之外还含有有益的食物组分。数种这些食物组分包括植物化学物和核苷酸,其为长期管饲膳食的患者提供多种益处。
植物化学物是在很多水果和蔬菜以及其它食物中发现的非营养性化合物。存在数千种植物化学物,其通常分为三个主要组。第一组是类黄酮和同源的酚和多酚化合物。第二组是类萜,例如类葫萝卜素和植物甾醇。第三组是生物碱和含硫化合物。植物化学物在体内是活跃的,通常发挥类似于抗氧化剂的作用。它们还在炎性过程、凝块形成、哮喘和糖尿病中发挥有益作用。研究者推理从食用植物化学物中获得最大益处,由于复杂的、天然的组合和潜在的协同作用,它们应当作为全食物的部分被食用。这可能部分解释了与食用全水果和蔬菜相关的健康益处。增加摄入水果和蔬菜与降低很多慢性疾病的风险相关。在一个实施方案中,为了增加本发明营养组合物的植物化学物分布,组合物包含含有这些化合物的多种水果和蔬菜。
作为腺苷三磷酸和相关分子的组分,核苷酸对于能量代谢也是必需的。核苷酸需求在快速细胞更新的组织中是最高的,例如肠和免疫细胞。核苷酸可以通过膳食摄入以及通过再利用途径获得。尽管需要高能量过程,但是核苷酸的内源性合成在健康个体中似乎是充足的。然而,在生长或应激情况下(例如肠损伤、败血症和免疫激发)需要外源性(膳食来源)的核苷酸。参见Kulkarni等人,TheRoleofDietarySourcesofNucleotidesinImmuneFunction:AReview(膳食来源的核苷酸在免疫功能中的作用:综述),JournalofNutrition,pp.1442S-1446S(1994)。长期管饲的多个部分的人群(老人、儿科人群、久坐的、卧床不起的和受伤的那些)可以特别受益于外源性核苷酸。长期管饲患者中常见的减少活动或久坐的生活方式与受损的免疫功能和改变的肠功能相关。
尽管内源性合成构成了核苷酸的主要来源,但是核苷酸还可以以动物和植物来源的所有食物中天然存在的核蛋白质形式获得,包括例如动物蛋白质、豌豆、酵母、豆和乳。此外,食物中RNA和DNA的浓度取决于细胞密度。因此,肉、鱼和种子含有比乳、蛋和水果更高的核苷酸。因此,器官肉、新鲜海鲜和干豆是丰富的食物来源。然而,设计的管饲是高度精制的,并且不含有核苷酸。因此,已经添加核苷酸以校正正常的肠和免疫功能的潜在变化。
如上述,除了骨的特别作用,人相关数据表明膳食摄入水果和蔬菜维持净碱性环境,其可以有助于调节代谢体内平衡。这种净碱性状态与增强维持至少老年个体中瘦体重相关。参见Dawson-HughesB等人,Alkalinedietsfavorleantissuemassinolderadults(碱性膳食有利于老年人的瘦组织重量),AmJClinNutr.Mar;87(3):662-5(2008)。因此,完全营养配方中磷(P)、钠(Na)、镁(Mg)、钾(K)和钙(Ca)的处理可以用于增加净碱性产生,进一步最小化内源性骨骼肌蛋白质水解以及维持瘦体重。
细胞能荷计划作为细胞的一个重要控制,以有利于合成代谢或分解代谢过程。细胞能荷被定义为能荷=(ATP+1/2ADP)/(ATP+ADP+AMP)[其中ATP、ADP和AMP分别表示腺苷5’-三磷酸、-二磷酸和-一磷酸]。代谢应激、营养应激或两者可以导致核苷酸从腺苷酸库中损耗,并且在这些情况下有条件地变成必需的。维持细胞能荷可以减少因代谢应激、营养应激或两者产生的分解代谢过程的上调,其包括蛋白质破坏。
AMP蛋白激酶(“AMPK”)是用作细胞能荷传感器的蛋白质,其对ATP/AMP以及磷酸肌酸/肌酸(“PCr”/“Cr”)的变化比值有应答,用于根据可用能量来优化细胞过程。特别地,AMPK可以靶向翻译控制骨骼肌蛋白质合成以及上调泛素蛋白酶体通路。
此外,核苷酸在压力性溃疡的营养处置中是有利的,其通过改善受伤部位对感染的抗性而实现。习惯性核苷酸补充可以抵消与生理应激相关的激素应答,导致增强的免疫应答。
还实施了在啮齿动物模型中膳食核苷酸对淋巴细胞功能和细胞免疫影响的广泛实验。现存的证据表明缺乏膳食核苷酸显著降低特异性和非特异性免疫应答。这些发现包括淋巴样细胞在对促细胞分裂原应答中降低的成熟作用和增殖,降低对细菌和真菌感染的抗性,和增加同种异体移植存活。
淋巴细胞分化和增殖可以通过特异性核苷酸刺激,反过来,核苷酸代谢可以受淋巴细胞活化和功能阶段的影响。此外,嘌呤和嘧啶的从头合成和再利用在受激的淋巴细胞中增加。作为证据,在喂食没有核苷酸的膳食的啮齿动物的未分化的骨髓和胸腺细胞中鉴定出用作未分化的T-细胞的确定标志物,末端脱氧核苷酰基转移酶(“TdT”)。
食用不含核苷酸的膳食的啮齿动物的体外和体内研究表明抑制细胞介导的免疫应答。取自不含核苷酸宿主的脾淋巴细胞表明对促细胞分裂原的增殖应答显著降低,降低白细胞介素-2(“IL-2”)产生以及更低水平的IL-2受体和Lyt-1表面标志物。IL-2是淋巴细胞的生长因子,而Lyt-1是辅助诱导性T-细胞免疫的标志物。迟发型皮肤过敏也更低。
通过添加RNA或尿嘧啶很大程度上逆转了这些应答,这表明嘧啶的强大作用和/或它们再利用的有限能力。另外,表明膳食核苷酸逆转损失的继发于蛋白质-热量营养不良的免疫应答大于单独的热量和蛋白质。但是,该逆转局限于嘧啶。
核苷酸在细菌和真菌感染中的作用研究也揭示了增强的抗性。相比食用不含核苷酸膳食的那些动物,食用含有核苷酸膳食的啮齿动物表明对静脉内感染金黄色葡萄球菌(Staphylococcusaureus)的显著抗性。观察到吞噬金黄色葡萄球菌能力的降低。而且,在类似感染白色念珠菌(Candidaalbicans)后,在食用不含核苷酸膳食的啮齿动物中观察到缩短的存活时间。添加RNA或尿嘧啶而不是腺嘌呤显示增加存活时间。
不含核苷酸膳食的免疫抑制作用还产生延长的啮齿动物的心脏同种异体移植存活以及与环胞菌素A的协同免疫抑制。这些发现表明对T-辅助细胞数量和功能的影响。已经提出了解释这些发现的多种作用机制。人们认为限制外源性核苷酸影响抗原加工的初发期并且通过对T-辅助诱导物的作用影响淋巴细胞增殖,如主要淋巴样器官中升高水平的TdT所证明的。这也表明了抑制未定型的T-淋巴细胞应答。同时,核苷酸限制可以导致细胞周期G期的T淋巴细胞的停滞,从而抑制淋巴细胞转变成S期,阻止必需的免疫信号。核苷酸限制还可以减弱天然杀伤(“NK”)细胞的细胞活性以及减弱巨噬细胞活性。
膳食的或外源性核苷酸还可以调节T-辅助细胞介导的抗体产生。调查核苷酸对体液免疫的作用的研究评述在体外和体内动物模型以及人系统的体外作用中鉴定出这些作用。在用T-细胞依赖性抗原处理的啮齿动物脾细胞中的体外发现表明在含有酵母RNA的培养基中产生抗体的细胞数量显著增加。正常菌株中的RNA添加证实了类似的结果,并且随着T-细胞消耗而失效。因此,在对T-细胞非依赖性的抗原或多克隆B细胞活化的应答中抗体没有增加。酵母RNA的特异性抗体应答归因于核苷酸。
还显示出在体外成年人外周血单核细胞对T-细胞依赖性抗原和刺激的应答中增加了免疫球蛋白的产生。特别地,这涉及增加的免疫球蛋白M(“IgM”)和G(“IgG”)的产生。IgM的产生在功能未成熟的脐带单核细胞对T-细胞依赖性刺激的应答中增加。
因此,在核苷酸缺乏的情况下,掺入膳食核苷酸可以潜在地挥发类似的体内免疫作用。对T-细胞依赖性抗原应答的抗体在坚持长期食用核苷酸膳食的啮齿动物中被抑制,并且核苷酸补充能快速恢复免疫功能。然而,补充所用的混合物显示出对抗原依赖性的抗原的体外抗体产生没有影响,这意味着核苷酸对局部、特异性免疫应答的作用。此外,在存在核苷酸的啮齿动物脾细胞中观察到分泌抗原特异性免疫球蛋白的细胞的数量显著增加。添加AMP、GMP或UMP还导致啮齿动物中IgG应答的增加。还显示出GMP增加IgM应答。在食用补充核苷酸的配方的早产儿中的研究显示在生命的第一个三个月中升高的循环水平的IgM和IgA,以及在生命的第一个月中更高浓度的抗α-酪蛋白和β-乳球蛋白的特异性IgG。对低应答抗体的特异性IgG水平在接受含有膳食核苷酸配方的正常婴儿中同样增加。
机械地认为体外和体内观察涉及核苷酸对T-辅助细胞在抗原呈递中的作用,通过与T-细胞的细胞表面分子相互作用来调节,抑制对抗原刺激应答的T-细胞的非特异性活化,和增加通过休眠T细胞介导的特异性抗体应答。因此,膳食核苷酸可以有利于T-细胞分化与T-辅助-2-细胞之间的平衡,其主要涉及B-细胞应答。因此,显然核苷酸以及植物化学物为患有任何上述病症的患者提供数种生理学益处。
技术人员认为任何已知的水果和蔬菜可以用于本发明营养组合物,只要所述的水果和蔬菜是植物化学物和/或核苷酸的来源。此外,技术人员还认为以有效量提供的水果和/或蔬菜为患者提供了足够量的植物化学物和/或核苷酸,以获得上述益处。
尽管已知的水果和蔬菜可以提供少量的核苷酸,但是由核苷酸产生的主要益处是通过添加额外来源的外源性核苷酸获得的。在一个实施方案中,某些肉可以用作外源性核苷酸的来源。例如,本公开的营养组合物包含至少约10mg/100kcal量的核苷酸。在一个实施方案中,营养组合物包含约13mg/100kcal至约19mg/100kcal的核苷酸。在一个实施方案中,营养组合物提供了约16mg/100kcal的核苷酸。在一个实施方案中,水果和蔬菜是核苷酸的唯一来源。在一个实施方案中,水果和蔬菜是核苷酸的部分来源。
类似地,本公开的营养组合物包含作为植物化学物来源的水果和蔬菜。在一个实施方案中,营养组合物包含有效量的植物化学物。
本发明的营养组合物中含有的水果可以包括任何已知的水果,例如但不限于苹果、香蕉、椰子、梨、杏、桃、蜜桃、梅李(plum)、樱桃、黑莓、覆盆子、桑葚、草莓、酸果蔓、越橘、葡萄、葡萄柚、猕猴桃、大黄、番木瓜、甜瓜、西瓜、石榴、柠檬、酸橙、橘子、橙或柑、红橘、番石榴、芒果、菠萝等。类似地,蔬菜可以包括任何已知的蔬菜,例如但不限于藻类、苋菜、芝麻菜(arugula)、抱子甘蓝(brusselssprouts)、甘蓝、芹菜莴苣、菊苣(radicchio)、水芥(watercress)、菠菜蘑菇、绿豆、青豆、豆、番茄、甜菜、胡萝卜、马铃薯、萝卜、芜菁甘蓝(rutabaga)、海带、芜菁(turnips)等。
如上面所提及的,本公开的营养组合物含有大量蛋白质。需要大量蛋白质支持合成代谢功能,维持瘦体重以及保证营养充足。在一个实施方案中,营养组合物含有蛋白质源。蛋白质源可以是膳食蛋白质,包括但不限于动物蛋白质(例如乳蛋白质、肉蛋白质或卵蛋白质)、植物蛋白质(例如大豆蛋白质、小麦蛋白质、粳米蛋白质和豌豆蛋白质)或其组合。在一个实施方案中,蛋白质选自乳清、鸡肉、玉米、酪蛋白酸盐、小麦、亚麻、大豆、角豆、豌豆或其组合。在另一个实施方案中,蛋白质是豌豆蛋白质或豌豆蛋白质分离物。
在一个实施方案中,包含植物蛋白质以进一步增强配方的净碱分布并且增加多种大量营养物源或模拟真实食物膳食,从而提供高质量的蛋白质混合物,其为支持生长和发育提供必需的营养需求。基于特别的植物蛋白质(例如豌豆蛋白质分离物)的营养分布,配方中可以包含的植物蛋白质源的量有限。例如,豌豆蛋白质的氨基酸分布包括所有必需氨基酸。豌豆蛋白质相对富含精氨酸,但含硫氨基酸(甲硫氨酸和半胱氨酸)有限。然而,可以例如将豌豆蛋白质分离物与含有足够的含硫氨基酸的完整蛋白质源(例如乳蛋白质或完整植物蛋白质)混合,以弥补该不足。油菜蛋白质(即分离物、水解物和浓缩物)是一种可以提供合适量含硫氨基酸的植物蛋白质,以进一步增加氨基酸分布,为患者递送必需蛋白质质量。此外,衍生自动物的蛋白质通常比植物蛋白质含有更丰富的含硫氨基酸。而且,对于与管饲相关的粘度限制的可能性和保证必需营养价值的蛋白质的需求,配方可以包含约10-50%的来自植物来源的蛋白质。
技术人员认为本发明营养组合物的蛋白质含量应当高于典型的长期管饲配方。例如,男女蛋白质的推荐膳食标准(“RDA”)是0.80g的优质蛋白质/kg体重/天,并且是基于可获得的氮平衡研究的细致分析。参见,NationalAcademyofSciences,InstituteofMedicine,FoodandNutritionBoard,DietaryReferenceIntakesforEnergy,Carbohydrate,Fiber,Fat,FattyAcids,Cholesterol,Protein,andAminoAcids(Macronutrients)(能量、碳水化合物、纤维、脂肪、脂肪酸、胆固醇、蛋白质和氨基酸(大量营养素)的膳食参考摄入),第10章(2005)。在一个实施方案中,本发明组合物给患者提供约1.0至2.5g/kg体重的量的蛋白质。在另一个实施方案中,本发明组合物给患者提供约1.5至2.0g/kg体重的量的蛋白质。因此,本发明组合物给患者提供接近2倍的男女蛋白质的RDA的量的蛋白质。
在一个实施方案中,提供一定量的蛋白质以提供每天约10至约30%的来自蛋白质的能量。在另一个实施方案中,提供一定量的蛋白质以提供每天约18%至约35%的来自蛋白质的能量。在另一个实施方案中,提供一定量的蛋白质以提供每天约15%至约25%的来自蛋白质的能量。取决于患者的体重和所需的来自给患者提供的蛋白质的能量,技术人员认为每天给患者施用的蛋白质的量可以不同。例如,每天给患者施用的蛋白质的量范围可以为约20g至约110g。在一个实施方案中,每天给患者施用的蛋白质的量的范围可以为约27g至约105g。下面提供的实施例进一步说明蛋白质的量可以如何根据患者的体重和所需的来自给患者提供的蛋白质的能量的量计算的。
如上面所讨论的,本公开的营养组合物应当是低热量的(例如通过少量膳食热量所表征的),以给患者提供适当的营养物,但控制体重增长,不危害患者健康(例如,肌骨骼感染、创伤修复、代谢等)。通常,低热量膳食常常提供1,000至1,200kcal/天。低热量膳食还可以通过每千克体重提供的能量来定义。例如,在成年人中每天小于20kcal/kg理想体重可以被认为是低热量的。参见,Dickerson等人,HypocaloricEnteralTubeFeedinginCriticallyIllObesePatients(危重病肥胖患者的低热量肠管饲),Nutrition,18:241(2002)。危重病肥胖患者的低热量肠管饲。这些陈述可能令人困惑,因为低热量膳食和低热量配方可能是两种不同的概念。例如,目标人群可以每日能量需求为约600至1,200kcal/天。ESPEN指南定义“低能量配方”为小于0.9kcal/mL的任何东西。本发明营养组合物的可以具有热密度范围为约0.3至约1.0kcal/mL。在一个实施方案中,营养组合物的热密度为约0.5至约0.8kcal/mL。
重量克分子渗透浓度是每千克溶剂中溶质的渗透压摩尔的量度(osmol/kg或Osm/kg)。在一个实施方案中,本发明营养组合物可以具有重量克分子渗透浓度小于或等于400mOsm/kg水。在另一个实施方案中,本发明营养组合物的重量克分子渗透浓度小于或等于380mOsm/kg水。
在一个实施方案中,营养组合物还包含姜黄素。姜黄素是香料姜黄(姜黄(curcumalonga))的组分,产生咖哩粉的黄色。姜黄素特别地显示出具有抗炎、抗氧化和抗蛋白质水解特性。对于经历瘦体质显著减少的长期管饲的儿科患者,姜黄素可以提供一定的减少骨骼肌蛋白质水解。重要的是姜黄素显示出拮抗核因子-Kβ(NF-Kβ)的上调,并且该基因不可分地触发诱导在卸荷过程中骨骼肌萎缩的细胞内信号级联放大。参见,Hunter等人,DisruptionofEithertheNfkb1ortheBcl3GeneInhibitsSkeletalMuscleAtrophy(Nfkb1或Bcl3基因的破坏抑制骨骼肌萎缩),J.Clin.Invest.,114(10):1504-11(2004)。
本公开的营养组合物还可以包含碳水化合物源。任何合适的碳水化合物可以用于本发明营养组合物,包括但不限于蔗糖、乳糖、葡萄糖、果糖、玉米浆固体、麦芽糊精、变性淀粉、直链淀粉、木薯淀粉、玉米或其组合。可以以一定量提供碳水化合物以便足以提供约40%至约60%的总能量。在一个实施方案中,以一定量提供碳水化合物以便足以提供约50%至约55%的营养组合物的总能量。
营养组合物还可以包含谷物。谷物可以包括例如全谷物,其可以从不同来源获得。不同来源可以包括粗粒麦粉、球果(cones)、磨光粉(grits)、面粉和微粒化的谷物(微粒化的面粉),并且可以源于谷物或假谷物。在一个实施方案中,谷物是水解的全谷物组分。本文所用的“水解的全谷物组分”是酶消化的全谷物组分或应用至少一种α-淀粉酶消化的全谷物组分,其中活性状态的α-淀粉酶对食物纤维没有显示水解活性。水解的全谷物组分可以进一步用蛋白酶消化,其中活性状态的蛋白酶对食物纤维没有显示水解活性。水解的全谷物组分是以液体、浓缩物、粉末、果汁、浓汤或其组合的形式提供的。
本发明营养组合物还包含脂肪源。脂肪源可以包括任何合适的脂肪或脂肪混合物。例如,脂肪源可以包括但不限于植物脂肪(例如橄榄油、玉米油、葵花子油、高油酸葵花子油、菜子油、低芥酸菜子油、榛子油、大豆油、棕榈油、椰子油、黑醋栗子油、琉璃苣油、卵磷脂等)、动物脂肪(例如乳脂肪)或其组合。脂肪源还可以是较少精制形式的上述脂肪(例如多酚含量的橄榄油)。可以以一定量提供脂肪以便足以提供约20%至约40%的总能量。在一个实施方案中,以一定量提供脂肪以便足以提供约25%至约30%的营养组合物的总能量。
在一个实施方案中,营养组合物进一步包含一种或多种益生元。益生元的非限制性实例包括阿拉伯胶、α-葡聚糖、阿拉伯半乳聚糖、β-葡聚糖、右旋糖酐、低聚果糖、岩藻糖基乳糖、低聚半乳糖、半乳甘露聚糖、低聚龙胆糖、低聚葡萄糖、瓜尔胶、菊糖、低聚异麦芽糖、乳新四糖、乳蔗糖、乳果糖、果聚糖、麦芽糊精、乳寡糖、部分水解的瓜尔胶、果胶低聚糖、抗性淀粉、回生淀粉、唾液酸低聚糖、唾液酰基乳糖、大豆低聚糖、糖醇、低聚木糖、它们的水解物或其组合。
营养组合物可以进一步包含一种或多种益生菌。益生菌的非限制性实例包括气球菌属、曲霉菌属、拟杆菌属、双歧杆菌属、念珠菌属、梭菌属、德巴利酵母属、肠球菌属、梭杆菌属、乳杆菌属、乳球菌属、明串珠菌属、蜜蜂球菌属、微球菌属、毛霉菌属、酒球菌属、片球菌属、青霉属、消化链球菌属、毕赤酵母属、丙酸杆菌属、Pseudocatenulatum、根霉菌属、酵母菌属、葡萄球菌属、链球菌属、球拟酵母属、魏斯氏菌属或其组合。
营养组合物中还可以存在一种或多种氨基酸。氨基酸的非限制性实例包括丙氨酸、精氨酸、天冬酰胺、天冬氨酸、瓜氨酸、半胱氨酸、谷氨酸、谷氨酰胺、甘氨酸、组氨酸、羟基脯氨酸、羟基丝氨酸、羟基酪氨酸、羟基赖氨酸、异亮氨酸、亮氨酸、赖氨酸、甲硫氨酸、苯丙氨酸、脯氨酸、丝氨酸、牛磺酸、苏氨酸、色氨酸、酪氨酸、缬氨酸或其组合。
营养组合物可以进一步包含一种或多种合生素,和/或鱼油的脂肪酸组分。鱼油的脂肪酸组分的非限制性实例包括二十二碳六烯酸(“DHA”)、二十碳五烯酸(“EPA”)或其组合。脂肪酸组分的其它非限制性来源包括鳞虾、ω-3的植物源、亚麻子、胡桃和藻类。
营养组合物中还可以存在一种或多种抗氧化剂。抗氧化剂的非限制性实例包括虾青素、类葫萝卜素、辅酶Q10(“CoQ10”)、类黄酮、谷胱甘肽Goji(枸杞(wolfberry))、橙皮苷、lactowolfberry、木酚素、叶黄素、番茄红素、多酚、硒、维生素A、维生素C、维生素E、玉米黄质或其组合。本发明营养组合物中可以提供的抗氧化剂的量为约500至约1,500IU/L。在一个实施方案中,提供的抗氧化剂的量为约1,000IU/L。
营养组合物还包含纤维或不同类型的纤维的混合物。纤维混合物可以含有可溶性和不溶性纤维的混合物。可溶性纤维可以包括例如低聚果糖、阿拉伯胶、菊糖等。不溶性纤维可以包括例如豌豆外纤维。
在本公开的实施方案中,提供了制备完全每日管饲喂养组合物的方法。该方法包括混合全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的量的来自蛋白质的能量),以形成混合物。该方法进一步包括处理混合物以形成管饲组合物,所述的组合物是完全每日喂养。所述的处理包括混合或液化,并且全食物组分可以是植物化学物和/或核苷酸源。全食物组分可以选自水果、蔬菜、肉、谷物或其组合。
在另一个实施方案中,本公开提供了改善患有潜在的医学病症的管饲儿科患者(包括那些长期管饲患者)的整体健康的方法。该方法包括给患者潜在的医学病症的管饲儿科患者施用低热量、完整每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。潜在的医学病症可以是脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、免疫缺陷、低骨密度、压力性溃疡、慢性创伤或其组合。
在另一个实施方案中,本公开提供了在长期管饲儿科患者中治疗和/或预防肥胖或最小化过度脂肪量增长的方法。该方法包括给肥胖或处于成为肥胖的风险中的管饲儿科患者施用低热量、完整每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,本公开提供了促进管饲儿科患者正常生长的方法。该方法包括给需要的管饲儿科患者施用低热量、完整每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,本公开提供了维持管饲儿科患者代谢体内平衡的方法。该方法包括给需要的患者施用低热量、完整每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,本公开提供了改善处于抗癫痫治疗的管饲儿科患者的骨健康的方法。该方法包括给处于抗癫痫治疗的管饲儿科患者施用低热量、完整每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素D源(其提供每升配方或每600kcal至少500IU的维生素D)和蛋白质源(其提供约18%至约35%的来自蛋白质的能量)。
在另一个实施方案中,提供了减少管饲儿科患者的健康护理费用的方法。该方法包括提供低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供每天约18%至约35%的来自蛋白质的能量)。该方法进一步包括给患有需要医学护理的潜在的医学病症的管饲儿科患者施用管饲配方。施用管饲配方改善患者的潜在的医学病症。在一个实施方案中,潜在的医学病症选自脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、延长的卧床休养、固定、截瘫/四肢瘫痪、免疫缺陷、低骨密度、压力性溃疡、慢性创伤或其组合。
在另一个实施方案中,提供了改善儿童的整体健康的方法。该方法包括给儿童施用管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供每天每千克体重约1.6至约3.6g蛋白质),其中配方每天给儿童提供约900至约1,100kcal。蛋白质源可以提供每千克体重约1.8g蛋白质或每kg体重约3.5g蛋白质。配方可以每天给儿童提供约1,000kcal。
在另一个实施方案中,提供了改善青春期前的青少年的整体健康。该方法包括给青春期前的青少年施用管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源(其提供每天每千克体重约1.25至约2.75g蛋白质),其中配方给青春期前的青少年提供每天约1,100至约1,300kcal。蛋白质源可以提供每千克体重约1.35g蛋白质或每千克体重约2.63克蛋白质。配方可以每天给青春期前的青少年提供约1,200kcal。
当给患有上述的多种健康问题的患者施用时,本公开的营养组合物可能是有益的。例如,给患有脑性瘫痪和其它神经肌肉障碍(其包括例如严重的脑损伤,例如与早产或发育迟缓相关的那些)儿童施用本公开的营养组合物将有助于儿童存活得更长。由于这些儿童接受包含含有真实食物组成的配方的长期管饲,这些儿童获得除了健康儿童所需的必需的大量营养物和微量营养物之外的食物生物活性的益处。因此,给儿童喂养这种类型的管饲配方可能对护理者和患者具有独特的情感吸引力。
通过应用改善的组合物和施用组合物的方法,可以解决个体中与肌肉、骨、神经和免疫健康相关的问题,所述的个体或是不活动的或是长期喂养标准管饲膳食的。事实上,改善的营养组合物提供了足够体积,增加的蛋白质和更高水平的某些微量营养物和大量营养物,而不提供过度的能量。这种配方给个体提供全食物组分,所述的全食物组分提供除了必需的大量营养物和微量营养物之外的生物活性的益处。
通过实例而非限制,下列实施例是本公开的营养组合物的举例说明。
具体实施方式
实施例
本公开的低热量、高蛋白质、混合的管饲组合物含有全食物组分。如上面所讨论的,本发明组合物还给患者提供大量蛋白质。例如,组合物可以提供推荐量的约1.5至2.0g蛋白质/kg体重。在一个实施方案中,营养组合物的热密度可以为约0.5-0.8kcal/mL,重量克分子渗透浓度</=380mOsm/kg水,核苷酸的量为约16mg/100kcal,维生素D的量为至少500IU/L,并且蛋白质源提供约18至约35%的来自蛋白质的能量。通常已知蛋白质提供每克蛋白质约4kcal能量。
在一个实施例中,10kg(22lb)患者每天消耗约600kcal。如果10kg患者接受蛋白质的范围为约1.5至2.0g/kg,那么该患者将预计每天消耗15-20克蛋白质。此外,为了每天提供18%的来自蛋白质的能量,10kg患者每天需要消耗27g蛋白质。因此,本公开的营养组合物可以含有27g蛋白质。
如果膳食需要量要求相同的10kg患者每天被提供25%来自蛋白质的能量,那么该10kg患者可以消耗含有37.5g蛋白质的本发明权利要求的营养组合物。
在另一个实施例中,25kg(55lb)患者每天消耗约1,000kcal。如果25kg患者接受蛋白质的范围为约1.5至2.0g/kg,那么该患者将预计每天消耗38-50克蛋白质。此外,为了每天提供18%来自蛋白质的能量,25kg患者每天需要消耗45g蛋白质。因此,本公开的营养组合物可以含有45g蛋白质。
如果膳食需要量要求相同的25kg患者每天被提供25%的来自蛋白质的能量,那么该25kg患者可以消耗含有62.5g蛋白质的本公开的营养组合物。
在另一个实施例中,40kg(88lb)患者每天消耗约1,200kcal。如果40kg患者接受蛋白质的范围为约1.5至2.0g/kg,那么该患者将预计每天消耗60-80克蛋白质。此外,为了每天提供18%的来自蛋白质的能量,40kg患者每天需要消耗54g蛋白质。因此,本公开的营养组合物可以含有54g蛋白质。
如果膳食需要量要求相同的40kg患者每天被提供25%的来自蛋白质的能量,那么该40kg患者可以消耗含有75g蛋白质的本公开的营养组合物。
应当理解的是,对本领域的技术人员而言,对本文所述的本发明的优选的实施方案的各种改变和修饰都是显而易见的。在不背离本主题的精神和范围并且不消除其预期优点的情况下可以进行这类变化和修饰。因此,这类变化和修饰均被所附的权利要求书所涵盖。
Claims (20)
1.完全每日喂养的管饲配方,其包含:
处理的全食物组分;
维生素或矿物质源;和
蛋白质源,其提供来自蛋白质的能量的量为约18%至约35%的配方的总能量。
2.权利要求1的管饲配方,其进一步包含每mL约0.5至约0.8kcal的热密度。
3.权利要求1或2的管饲配方,其中处理的全食物组分选自处理的水果、处理的蔬菜、处理的肉、处理的谷物及其组合。
4.上述权利要求中任意一项的管饲配方,其中蛋白质选自基于乳制品的蛋白质、基于植物的蛋白质、基于动物的蛋白质、人工蛋白质及其组合。
5.权利要求4的管饲配方,其中基于乳制品的蛋白质选自酪蛋白、酪蛋白酸盐、酪蛋白水解物、乳清、乳清水解物、乳清浓缩物、乳清分离物、乳蛋白质浓缩物、乳蛋白质分离物及其组合。
6.权利要求4的管饲配方,其中基于植物的蛋白质选自大豆蛋白质、豌豆蛋白质、油菜蛋白质、小麦和分级的小麦蛋白质、玉米蛋白质、玉米醇溶蛋白质、粳米蛋白质、燕麦蛋白质、马铃薯蛋白质、花生蛋白质、青豆粉、绿豆粉、螺旋藻、衍生自蔬菜、豆、乔麦、小扁豆、干豆的蛋白质、单细胞蛋白质及其组合。
7.上述权利要求中任意一项的管饲配方,其进一步包含植物营养物,所述的植物营养物选自类黄酮、同源的酚化合物、多酚化合物、类萜、生物碱、含硫化合物及其组合。
8.上述权利要求中任意一项的管饲配方,其进一步包含核苷酸,所述的核苷酸选自脱氧核糖核酸亚基、核糖核酸的亚基、聚合形式的DNA和RNA及其组合,其中核苷酸以至少约10mg/100kcal的量提供。
9.制备管饲组合物的方法,该方法包括:
混合全食物组分、维生素或矿物质源和蛋白质源以形成混合物,所述的蛋白质源提供约18%至约35%的量的来自蛋白质的能量;和
处理混合物以形成管饲组合物,其是完全每日喂养。
10.权利要求9的方法,其中全食物组分选自水果、蔬菜、肉、谷物及其组合。
11.权利要求9或10的方法,其中处理包括混合。
12.权利要求9至11中任意一项的方法,其中全食物组分是植物化学物和/或核苷酸来源。
13.权利要求9至12中任意一项的方法,其中管饲配方具有每mL约0.5至约0.8kcal的热密度。
14.权利要求9至13中任意一项的方法,其中维生素或矿物质源包括维生素D源,其提供至少500IU。
15.权利要求9至14中任意一项的方法,其中管饲配方包含至少约10mg/100kcal的量的核苷酸。
16.改善患有潜在的医学病症的管饲儿科患者的整体健康的方法,该方法包括:
给患有潜在的医学病症的管饲儿科患者施用低热量、完全每日喂养的管饲配方,所述的配方包含处理的全食物组分、维生素或矿物质源和蛋白质源,所述的蛋白质源提供约18%至约35%的来自蛋白质的能量。
17.权利要求16的方法,其中潜在的医学病症选自脑性瘫痪、长势不能、神经肌肉障碍、脑损伤、发育迟缓、免疫缺陷、低骨密度、压力性溃疡、慢性创伤、长期管饲患者及其组合。
18.权利要求16或17的方法,其中管饲配方具有每mL约0.5至约0.8kcal的热密度。
19.权利要求16至18中任意一项的方法,其中维生素和矿物质源包括维生素D源,其提供每升配方或每600kcal至少500IU的维生素D。
20.权利要求16至19中任意一项的方法,其中管饲配方包含至少约10mg/100kcal的量的核苷酸。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35917910P | 2010-06-28 | 2010-06-28 | |
US61/359,179 | 2010-06-28 | ||
US37182910P | 2010-08-09 | 2010-08-09 | |
US61/371,829 | 2010-08-09 | ||
US201161447155P | 2011-02-28 | 2011-02-28 | |
US61/447,155 | 2011-02-28 | ||
US201161466019P | 2011-03-22 | 2011-03-22 | |
US61/466,019 | 2011-03-22 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800322480A Division CN102958386A (zh) | 2010-06-28 | 2011-06-28 | 低热量、高蛋白质营养组合物及其应用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105747218A true CN105747218A (zh) | 2016-07-13 |
Family
ID=44509597
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800322480A Pending CN102958386A (zh) | 2010-06-28 | 2011-06-28 | 低热量、高蛋白质营养组合物及其应用方法 |
CN201610136619.4A Pending CN105747218A (zh) | 2010-06-28 | 2011-06-28 | 低热量、高蛋白质营养组合物及其应用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800322480A Pending CN102958386A (zh) | 2010-06-28 | 2011-06-28 | 低热量、高蛋白质营养组合物及其应用方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9486003B2 (zh) |
EP (1) | EP2584920B1 (zh) |
JP (2) | JP2013529475A (zh) |
CN (2) | CN102958386A (zh) |
AU (2) | AU2011276545A1 (zh) |
BR (1) | BR112012033422B8 (zh) |
CA (1) | CA2801208C (zh) |
DK (1) | DK2584920T3 (zh) |
ES (1) | ES2660037T3 (zh) |
MX (1) | MX339316B (zh) |
PH (1) | PH12012502278A1 (zh) |
RU (1) | RU2013103517A (zh) |
SG (1) | SG186086A1 (zh) |
WO (1) | WO2012006074A1 (zh) |
ZA (1) | ZA201300690B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110742266A (zh) * | 2019-11-11 | 2020-02-04 | 江南大学 | 一种辅助调节肠道免疫功能的全营养配方食品 |
CN112568444A (zh) * | 2020-11-20 | 2021-03-30 | 格乐瑞(无锡)营养科技有限公司 | 一种缓解肌肉流失的组合物及其制备方法 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2660037T3 (es) | 2010-06-28 | 2018-03-20 | Nestec S.A. | Composiciones nutritivas hipocalóricas, de alto contenido en proteínas y procedimientos para su utilización |
EP4074355A1 (en) * | 2011-04-20 | 2022-10-19 | Amgen Inc. | Autoinjector apparatus |
SG10201604458VA (en) | 2012-03-26 | 2016-07-28 | Axcella Health Inc | Nutritive fragments, proteins and methods |
JP2015518470A (ja) | 2012-03-26 | 2015-07-02 | プロニュートリア・インコーポレイテッドPronutria, Inc. | 栄養タンパク質および方法 |
AU2013240183B2 (en) | 2012-03-26 | 2016-10-20 | Axcella Health Inc. | Charged nutritive proteins and methods |
EP2831102A4 (en) | 2012-03-26 | 2015-12-02 | Pronutria Inc | NUTRIENT FRAGMENTS, NUTRIENT PROTEINS AND METHODS |
ES2694426T3 (es) | 2012-10-04 | 2018-12-20 | Abbott Laboratories | Procedimientos para mejorar el efecto de EGCg en la mitigación de la pérdida de músculo esquelético |
FR2996419B1 (fr) * | 2012-10-09 | 2015-05-29 | Internat Nutrition Res Company | Produit dietetique destine a etre administre aux personnes obeses recemment operees en chirurgie bariatrique |
AU2014240730B2 (en) * | 2013-03-27 | 2018-11-15 | Nutritional Growth Solutions Ltd | Nutritional supplement for growth enhancement |
SG11201601999UA (en) | 2013-09-25 | 2016-04-28 | Pronutria Inc | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control |
CZ305468B6 (cs) | 2014-03-19 | 2015-10-14 | Zlkl, S.R.O. | Výsuvná spojovací tyč řízení |
CN105212042A (zh) * | 2014-06-30 | 2016-01-06 | 罗汉斐 | 一种小麦发酵营养食品及其制作方法 |
US9446100B2 (en) | 2015-02-13 | 2016-09-20 | Eastern Vision Limited | Dietary supplements and formulations |
CN105901144A (zh) * | 2015-12-14 | 2016-08-31 | 威海百合生物技术股份有限公司 | 一种具有抑菌作用的高蛋白食品的制备方法 |
TWI634845B (zh) * | 2016-12-27 | 2018-09-11 | 信元製藥股份有限公司 | 均質泥狀寵物膳食及其製造方法 |
US11541025B2 (en) | 2017-04-10 | 2023-01-03 | Societe Des Produits Nestle S.A. | Method of preparing a composition comprising ferulic acid |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
US20200345056A1 (en) * | 2018-01-26 | 2020-11-05 | Abbott Laboratories | Tube feeding composition and method for preparation thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018618A2 (en) * | 1994-01-10 | 1995-07-13 | Abbott Lab | Enteral formula with ribo-nucleotides |
US5723446A (en) * | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
WO1999058001A1 (en) * | 1998-05-13 | 1999-11-18 | Novartis Nutrition Ag | Nutritional product for a person having renal failure |
CN1257731A (zh) * | 1999-12-22 | 2000-06-28 | 王爱民 | 一种适用于管饲病人的全能营养素及其生产工艺 |
CN1330881A (zh) * | 2000-06-29 | 2002-01-16 | 王爱民 | 一种全营养膳 |
BG548Y1 (bg) * | 1997-03-31 | 2002-07-31 | Тошка Й. Масларска | Хранителен продукт за ентерално хранене |
WO2004103383A1 (en) * | 2003-05-22 | 2004-12-02 | N.V. Nutricia | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
WO2005110124A1 (en) * | 2004-04-15 | 2005-11-24 | Abbott Laboratories | Composition and methods for nutritional management of patients with hepatic disease |
CN101522056A (zh) * | 2006-10-19 | 2009-09-02 | 雀巢产品技术援助有限公司 | 老年人的长期喂养 |
WO2009135959A1 (es) * | 2008-05-07 | 2009-11-12 | Katry Inversiones, S.L. | Producto alimenticio para la nutrición por vía enteral u oral del paciente diabético |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57110176A (en) | 1980-12-27 | 1982-07-08 | Snow Brand Milk Prod Co Ltd | Nutrious food composition for tube feeding |
US5268365A (en) | 1988-03-11 | 1993-12-07 | Rudolph Frederick B | Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance |
SE463593B (sv) * | 1988-05-27 | 1990-12-17 | Semper Ab | Sondnaering innehaallande betfibrer och foerfarande foer framstaellning daerav |
US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
JP2004500421A (ja) | 2000-04-18 | 2004-01-08 | ソシエテ デ プロデユイ ネツスル ソシエテ アノニム | 栄養モジュール |
JP3907098B2 (ja) * | 2001-02-13 | 2007-04-18 | 株式会社大塚製薬工場 | 栄養飲料またはゼリー |
US20030104033A1 (en) | 2001-07-13 | 2003-06-05 | Lai Chon-Si | Enteral formulations |
EP1281325A1 (en) | 2001-07-30 | 2003-02-05 | Societe Des Produits Nestle S.A. | Nutritional composition preventing bacterial overgrowth |
JP3724740B2 (ja) * | 2002-06-20 | 2005-12-07 | 日清キョーリン製薬株式会社 | コエンザイムq10を含有する経管経腸栄養剤 |
JP2006033349A (ja) * | 2004-07-15 | 2006-02-02 | Nippon Dempa Kogyo Co Ltd | 逓倍型の水晶発振器 |
JP5574561B2 (ja) * | 2004-09-22 | 2014-08-20 | 味の素株式会社 | 総合経腸栄養組成物 |
JP2006104147A (ja) | 2004-10-07 | 2006-04-20 | Otsuka Pharmaceut Factory Inc | 経口・経腸栄養組成物 |
WO2008046871A2 (en) | 2006-10-19 | 2008-04-24 | Nestec S.A. | Methods of providing long-term nutrition |
WO2009013559A1 (en) | 2007-07-23 | 2009-01-29 | Cellectis | Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof |
CN101938911B (zh) | 2007-12-05 | 2014-07-02 | 荷兰纽迪希亚公司 | 富含蛋白的基于胶束酪蛋白的液体肠营养组合物 |
WO2009113845A1 (en) | 2008-03-12 | 2009-09-17 | N.V. Nutricia | High protein liquid enteral nutritional composition |
US20090264520A1 (en) | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
JP5341601B2 (ja) * | 2008-04-22 | 2013-11-13 | 三栄源エフ・エフ・アイ株式会社 | 液状食品用ゲル化剤及びゲル状食品の製造方法 |
MX2011004141A (es) | 2008-10-17 | 2011-05-24 | Nestec Sa | Composiciones de proteina de suero lacteo, metodos y usos. |
ES2660037T3 (es) | 2010-06-28 | 2018-03-20 | Nestec S.A. | Composiciones nutritivas hipocalóricas, de alto contenido en proteínas y procedimientos para su utilización |
-
2011
- 2011-06-28 ES ES11730513.6T patent/ES2660037T3/es active Active
- 2011-06-28 CN CN2011800322480A patent/CN102958386A/zh active Pending
- 2011-06-28 RU RU2013103517/13A patent/RU2013103517A/ru not_active Application Discontinuation
- 2011-06-28 CA CA2801208A patent/CA2801208C/en active Active
- 2011-06-28 AU AU2011276545A patent/AU2011276545A1/en not_active Abandoned
- 2011-06-28 SG SG2012087474A patent/SG186086A1/en unknown
- 2011-06-28 MX MX2012015080A patent/MX339316B/es active IP Right Grant
- 2011-06-28 DK DK11730513.6T patent/DK2584920T3/en active
- 2011-06-28 BR BR112012033422A patent/BR112012033422B8/pt active IP Right Grant
- 2011-06-28 US US13/805,795 patent/US9486003B2/en active Active
- 2011-06-28 PH PH1/2012/502278A patent/PH12012502278A1/en unknown
- 2011-06-28 CN CN201610136619.4A patent/CN105747218A/zh active Pending
- 2011-06-28 EP EP11730513.6A patent/EP2584920B1/en not_active Revoked
- 2011-06-28 WO PCT/US2011/042148 patent/WO2012006074A1/en active Application Filing
- 2011-06-28 JP JP2013518567A patent/JP2013529475A/ja active Pending
-
2013
- 2013-01-25 ZA ZA2013/00690A patent/ZA201300690B/en unknown
-
2015
- 2015-05-28 AU AU2015202897A patent/AU2015202897B2/en active Active
-
2016
- 2016-04-21 JP JP2016085348A patent/JP6852980B2/ja active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723446A (en) * | 1993-12-23 | 1998-03-03 | Nestec Ltd. | Enteral formulation designed for optimized nutrient absorption and wound healing |
WO1995018618A2 (en) * | 1994-01-10 | 1995-07-13 | Abbott Lab | Enteral formula with ribo-nucleotides |
BG548Y1 (bg) * | 1997-03-31 | 2002-07-31 | Тошка Й. Масларска | Хранителен продукт за ентерално хранене |
WO1999058001A1 (en) * | 1998-05-13 | 1999-11-18 | Novartis Nutrition Ag | Nutritional product for a person having renal failure |
CN1257731A (zh) * | 1999-12-22 | 2000-06-28 | 王爱民 | 一种适用于管饲病人的全能营养素及其生产工艺 |
CN1330881A (zh) * | 2000-06-29 | 2002-01-16 | 王爱民 | 一种全营养膳 |
WO2004103383A1 (en) * | 2003-05-22 | 2004-12-02 | N.V. Nutricia | A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
WO2005110124A1 (en) * | 2004-04-15 | 2005-11-24 | Abbott Laboratories | Composition and methods for nutritional management of patients with hepatic disease |
CN101522056A (zh) * | 2006-10-19 | 2009-09-02 | 雀巢产品技术援助有限公司 | 老年人的长期喂养 |
WO2009135959A1 (es) * | 2008-05-07 | 2009-11-12 | Katry Inversiones, S.L. | Producto alimenticio para la nutrición por vía enteral u oral del paciente diabético |
Non-Patent Citations (2)
Title |
---|
A.H.恩斯明格等: "《疾病与饮食》", 30 June 1989, 农业出版社 * |
AINSLEY MALONE: "Enteral Formula Selection: A Review of Selected Product Categories", 《PRACTICAL GASTROENTEROLOGY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110742266A (zh) * | 2019-11-11 | 2020-02-04 | 江南大学 | 一种辅助调节肠道免疫功能的全营养配方食品 |
CN110742266B (zh) * | 2019-11-11 | 2022-11-01 | 江南大学 | 一种辅助调节肠道免疫功能的全营养配方食品 |
CN112568444A (zh) * | 2020-11-20 | 2021-03-30 | 格乐瑞(无锡)营养科技有限公司 | 一种缓解肌肉流失的组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2584920A1 (en) | 2013-05-01 |
EP2584920B1 (en) | 2017-12-13 |
DK2584920T3 (en) | 2018-01-22 |
CN102958386A (zh) | 2013-03-06 |
BR112012033422A2 (pt) | 2015-09-08 |
SG186086A1 (en) | 2013-01-30 |
US9486003B2 (en) | 2016-11-08 |
WO2012006074A1 (en) | 2012-01-12 |
AU2015202897B2 (en) | 2016-06-02 |
PH12012502278A1 (en) | 2013-02-04 |
JP6852980B2 (ja) | 2021-04-14 |
MX2012015080A (es) | 2013-02-12 |
RU2013103517A (ru) | 2014-08-10 |
CA2801208C (en) | 2016-10-04 |
JP2013529475A (ja) | 2013-07-22 |
AU2011276545A1 (en) | 2012-12-13 |
BR112012033422B1 (pt) | 2018-08-21 |
US20130203664A1 (en) | 2013-08-08 |
CA2801208A1 (en) | 2012-01-12 |
AU2015202897A1 (en) | 2015-06-18 |
MX339316B (es) | 2016-05-20 |
ES2660037T3 (es) | 2018-03-20 |
JP2016214237A (ja) | 2016-12-22 |
ZA201300690B (en) | 2016-11-30 |
BR112012033422B8 (pt) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105747218A (zh) | 低热量、高蛋白质营养组合物及其应用方法 | |
JP5990241B2 (ja) | 安定な増粘剤配合物 | |
JP5964824B2 (ja) | 経管栄養製剤を投与する方法 | |
CN103458887A (zh) | 用于增加精氨酸水平的营养组合物及其使用方法 | |
US20140056862A1 (en) | Nutritional compositions having alpha-hica and alpha-ketoglutarate | |
MX2013011834A (es) | Composiciones nutricionales que incluyen acidos grasos de cadena ramificada y metodos para utilizar las mismas. | |
CN103596440A (zh) | 含有外源性乳脂肪球膜组分的营养组合物 | |
CN104206946A (zh) | 用于促进肠微生物群平衡和健康的营养组合物 | |
CN102883626A (zh) | 包括高蛋白质成分和外源性核苷酸的营养组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190711 Address after: Vevey Applicant after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160713 |
|
RJ01 | Rejection of invention patent application after publication |